Document:

exv4w15

Exhibit 4.15

CONFIDENTIAL TREATMENT REQUESTED

     Indicates that certain information contained herein has been omitted and filed separately with
the Securities and Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

      

Service Agreement for 2011 Securities Practitioner Qualification Exams

	 	 	 
	Party A:

	 	Securities Association of China
	Address:

	 	2nd Floor, B Tower, Fukai Plaza, 19 Jinrong Street, Xicheng District, Beijing
	 	 	 
	Party B:

	 	ATA Testing Authority (Beijing) Limited (“ATA”)
	Address:

	 	16th Floor, E Tower, No. 6 Gongyuan West Street, Jianguomennei, Beijing

Securities Association of China is the holder of Securities Practitioner Qualification Exams. ATA
is a specialty supplier of exam technology services and exam delivery services. Based on the
principles of rigorousness, scientific methodology and efficiency, and through friendly
negotiation, Party A and Party B hereby enter into this Agreement for mutual observance.

Article 1 In accordance with relevant State laws and regulations and the overall arrangement on
Securities Practitioner Qualification Exams (“Exam” or “Qualification Exam”), Party A hereby
entrusts Party B to perform relevant services for the exams of 2011. The exams will be performed
on computers (“Computer-based Exam”).

Article 2 Services entrusted by Party A to Party B in connection with the exams include: providing
technical services for exams, handling exam takers’ registrations and payment, issuing and mailing
receipts, arranging exam venues, arranging exam premises’ layout, producing admission cards,
arranging exams, collecting and processing exam score, carrying out statistical and analysis work
for the exams, evaluating exam papers, and other work deemed necessary by Party A.

Article 3 Party A will formulate and inform Party B of the standards and regulations of the
Qualification Exam and the Computer-based Exam.

Article 4 Party B shall perform services for Party A on the basis of the above Article 2 and such
services shall be consistent with the requirements in Party A’s announcement in respect of each
specific exam.

Article 5 The services to be provided by Party B should be examined and supervised by Party A.
Party B should promptly notify Party A of relevant information regarding action against Exam Takers
that violated rules.

Article 6 Party B shall, according to the principle of ensuring smooth administration of exams,
formulate Service Criteria for Securities Practitioner Qualification Exams and specific working
plan for each exam and submit to Party A for its records.

1

 

Article 7 Party B will accept registrations from exam takes (“Exam Takers”) by means of online
registration and the payment relating thereto may be made via bank transfer or online payment.
Party B should take effective measures to ensure smooth registration.

Article 8 Party A and Party B should enter into a joint fund management agreement with the party
that collects the registration fee so that the three parties may jointly manage the funds. The
account for the registration fee collection should be named according to Party A’s exam and shall
be used for fee collection and accounts transfers only. Party B shall not withdraw funds from the
registration fee account by any means without Party A’s approval.

Article 9

	 
	Bank account holder:

	Bank name:

	Account number:

Article 10 Party B shall arrange sufficient manpower to assist Party A in issuing and mailing
receipts for registration fees to Exam Takers.

Article 11 Party B is required to create a specific window on the exam registration website so that
Party A will be informed of the registration status from time to time.

Article 12 Party B is required to provide the information of the registered Exam Takers within one
month of the completion of registration. The information security officer of Party A shall go to
Party B’s site to examine, among others, the data storage and backup record, and supervise the
destruction of exam data throughout the entire process and the completion of ATA’s List of
Eliminated Exam Results by Party B’ data administrator.

Article 13 Party B shall, according to Party A’s express standards and requirements on exam venues
and exam premises, arrange exam venues and exam premises based on the principles of facilitating
Exam Takers. The exam venues should be conveniently located, have a clean environment, and have
sufficient hardware facilities to ensure smooth conduction of exams.

Article 14 The exam venues and exam premises should be inspected and accepted by Party A; those
considered not meeting relevant standards and requirements should be corrected or replaced by ATA.

Article 15 Party B shall enter into contracts with the exam venues and exam premises it selected,
and shall take proper measures to ensure the performance of the contracts.

Article 16 Party B shall arrange the Exam Takers to attend the exam, and shall take the effective
measures listed below to ensure the success of the exam:

(1) Exam premises shall be equipped with sufficient monitoring teachers who are required to fulfill
the duty to keep the exam premises in order;

2

 

(2) Exam premises shall be equipped with on-site video capture facilities and have integrated video
capture standard;

(3) Exam premises shall be equipped with remote surveillance equipment;

(4) Each exam premises shall be equipped with sufficient technicians;

(5) Each exam premises shall be equipped with sufficient computers and backups to meet the need of
exams. After an exam is started, computers in premises should be able to work properly, and the
number of malfunctioning computers (such as computer breakdown) shall not exceed 0.1% of the total
computers used in the exam. Moreover, upon adoption of preventive and corrective measures, all the
computers shall be in proper working conditions during the exam; and

(6) Other preventive measures in other comparable exams.

Article 17 Party B shall, through the exam premises administrator, read out the exam rules
formulated by Party A to exam takers.

Article 18 Party B shall, within 5 working days after the exam is over, finish the test paper
review and submit to Party A the exam data, including exam result, analysis of exam data,
disciplinary action against breach of exam discipline. The information security officer of Party A
shall, within 15 working days after the exam is over, go to Party B’s site to examine, among
others, the data storage and backup record, and supervise the destruction of exam data throughout
the entire process and the completion of ATA’s List of Eliminated Exam Results by Party B’ data
administrator.

Article 19 Party A may entrust Party B with accepting inquiries from exam takers about the exam
matters; without permission of Party A, Party B may not engage in any publicity activity relating
to the exam or accept any inquiries about exam results.

Article 20

	 
	Bank account name:

	Bank name:

	Account number:

Article 21 Each party shall respect and protect the other party’s intellectual property rights and
shall only use the other party’s intellectual property rights to the extent expressly authorized or
agreed and shall make best endeavors to protect the other party’s intellectual property rights.

Article 22 Both parties shall undertake that their respective own intellectual property rights will
not infringe upon any interest of any third party; if any third party raises any objection,
institutes any action or applies for arbitration, which causes any loss to a party hereto, the
party at fault shall be solely liable for damages.

3

 

Article 23 Party A shall absolutely own the intellectual property rights to the exam question pool
and the exams it provided, irrespective of whether this agreement is terminated or not, and Party B
may not use or divulge in any way any information relating to the exam question pool and the exams
that it learned during the performance of the terms of this agreement without the written consent
of Party A.

Article 24 Irrespective of whether this agreement is terminated or not, each party shall treat as
confidential any Confidential Information of the other party that it obtained during the
performance of this agreement. The party aware of such Confidential Information may communicate
such Confidential Information to its relevant employees or relevant professionals engaged by it,
provided that it guarantee that such personnel shall agree to be bound by this agreement and not to
divulge the Confidential Information in any manner.

Article 25 The “Confidential Information” hereunder means the exam question pool, test paper,
financial information of the parties, exam takers’ information, exam data and result relating to
the products and services provided by the parties in connection with the exam work, as well as
proprietary technology, software programs and working.

Article 26 The test technology and software owned by Party B to provide test related services shall
be kept under strict confidential arrangement and reliable technical support shall be provided to
ensure the secrecy of intellectual property rights of Party A and other confidential matters under
this agreement.

Article 27 If Party B breaches Articles 3 to 19 hereof and the circumstance of such breach is
moderate, Party A shall give admonition and ask Party B to make a correction within a prescribed
time limit; if the breach is serious or if Party B refuses to accept such admonition and fails to
make a correction, Party A shall have the right to unilaterally rescind this agreement.

Article 28 If Party B violates Articles 21 to 25 hereof, and such action results in serious
consequences and prevents the normal administration of the exam, Party A shall have the right to
terminate this agreement and to demand that Party B indemnify Party A for the losses arising
therefrom which shall be equal to the fees already paid by Party A to Party B.

Article 29 If Party B cooperates with any third party in connection with the exam matters delegated
by Party A, and Party A’s interest is impaired by such third party, Party B shall be liable for
damages.

Article 30 Neither party shall be liable for any delay in performing, or any failure to perform,
any of its obligations under this agreement if such delay or failure arises from force majeure.

Article 31 Any dispute arising from the content or the performance of this agreement shall be
settled through active consultations between the parties. If consultations come to no avail, either
party may institute legal action with a court located near where Party A is situated.

4

 

Article 32 During the performance of this agreement, Party A, depending on its needs, has the right
to delegate to any third party the exam work not expressly set forth in this agreement.

Article 33 If the terms of this agreement conflict with an announcement regarding exam content
issued by Party A during the performance hereof, the announcement issued by Party A shall prevail.

Article 34 Either party has the right to terminate this agreement if the other party becomes
bankrupt or stops doing business during the performance of this agreement; the party that becomes
bankrupt or stops doing business shall indemnify the other party for its relevant loss.

Article 35 Any matters not covered herein shall be provided for in a supplementary agreement.

Article 36 This agreement will come into force upon signature and seal of both parties and will be
valid for a period of 1 year.

Article 37 This agreement shall be executed in 4 counterparts, with each party holding 2
counterparts.

	 	 	 
	Party A: Securities Association of China

	 	Party B: ATA Testing Authority (Beijing) Limited
	 
	 	 
	Authorized representative of Party A:

	 	Authorized representative of Party B:
	(signature/official seal):

	 	(signature/official seal):
	 
	 	 
	 
	 	 
	Signature (handwritten):

	 	Signature (handwritten):
	 
	 	 
	Date: June 8, 2011

	 	Date: June 8, 2011

5exv4w1

Exhibit 4.1

Execution Version

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

1.625% Convertible Senior Notes due 2016

Purchase Agreement

June 9, 2011

J.P. Morgan Securities LLC

Merrill Lynch, Pierce, Fenner & Smith Incorporated

Morgan Stanley & Co. LLC

Deutsche Bank Securities Inc.

RBC Capital Markets, LLC

Wells Fargo Securities, LLC
 As
Representatives of the
 several
Initial Purchasers listed
 in
Schedule 1 hereto

c/o J.P. Morgan Securities LLC

383 Madison Avenue

New York, New York 10179

Ladies and Gentlemen:

     Integra LifeSciences Holdings Corporation, a Delaware corporation (the “Company”), proposes to
issue and sell to the several initial purchasers listed in Schedule 1 hereto (the “Initial
Purchasers”), for whom you are acting as representatives (the “Representatives”), $200,000,000
principal amount of its 1.625% Convertible Senior Notes due 2016 (the “Underwritten Securities”)
and, at the option of the Initial Purchasers, up to an additional $30,000,000 principal amount of
its 1.625% Convertible Senior Notes due 2016 (the “Option Securities”) solely to cover
over-allotments, if and to the extent that the Initial Purchasers shall have determined to exercise
the option to purchase such 1.625% Convertible Senior Notes due 2016 granted to the Initial
Purchasers in Section 2 hereof. The Underwritten Securities and the Option Securities are herein
referred to as the “Securities”. The Securities will be convertible into cash or a combination of
cash and shares (the “Underlying Securities”) of common stock of the Company, par value $0.01 per
share (the “Common Stock”). The Securities will be issued pursuant to an Indenture to be dated as
of June 15, 2011 (the “Indenture”) between the Company and Wells Fargo Bank, National Association,
as trustee (the “Trustee”).

     In connection with the offering of the Underwritten Securities, the Company and four of the
Initial Purchasers or affiliates thereof, (the “Call Spread Counterparties”) are entering into
convertible note hedge transactions and warrant transactions pursuant to convertible note hedge
confirmations and warrant confirmations, each dated the date hereof (the “Base Call Spread
Confirmations”), and in connection with the issuance of any Option Securities, the Company and

 

2

the
Call Spread Counterparties may enter into additional convertible note hedge transactions and
warrant transactions pursuant to convertible note hedge confirmations and warrant confirmations,
each to be dated the date of issuance of such Option Securities (together with the Base Call Spread
Confirmations, the “Call Spread Confirmations”).

     The Company hereby confirms its agreement with the several Initial Purchasers concerning the
purchase and sale of the Securities, as follows:

     1. The Securities will be sold to the Initial Purchasers without being registered under the
Securities Act of 1933, as amended (the “Securities Act”), in reliance upon an exemption therefrom.
The Company has prepared a preliminary offering memorandum dated June 9, 2011 (the “Preliminary
Offering Memorandum”) and will prepare an offering memorandum dated the date hereof (the “Offering
Memorandum”) setting forth information concerning the Company and the Securities. Copies of the
Preliminary Offering Memorandum have been, and copies of the Offering Memorandum will be, delivered
by the Company to the Initial Purchasers pursuant to the terms of this Agreement. The Company
hereby confirms that it has authorized the use of the Preliminary Offering Memorandum, the other
Time of Sale Information (as defined below) and the Offering Memorandum in connection with the
offering and resale of the Securities by the Initial Purchasers in the manner contemplated by this
Agreement. References herein to the Preliminary Offering Memorandum, the Time of Sale Information
and the Offering Memorandum shall be deemed to refer to and include any document incorporated by
reference therein.

     At or prior to the time when sales of the Securities were first made (the “Time of Sale”), the
Company had prepared the following information (collectively, the “Time of Sale Information”): the
Preliminary Offering Memorandum, as supplemented and amended by the written communications listed
on Annex B hereto.

     2. Purchase and Resale of the Securities by the Initial Purchasers. (a) The Company
agrees to issue and sell the Underwritten Securities to the several Initial Purchasers as provided
in this Agreement, and each Initial Purchaser, on the basis of the representations, warranties and
agreements set forth herein and subject to the conditions set forth herein, agrees, severally and
not jointly, to purchase from the Company the respective principal amount of Underwritten
Securities set forth opposite such Initial Purchaser’s name in Schedule 1 hereto at a price equal
to 97.25% of the principal amount thereof (the “Purchase Price”) plus accrued interest, if any,
from June 9, 2011 to the Closing Date (as defined below).

     In addition, the Company agrees to issue and sell the Option Securities to the several Initial
Purchasers as provided in this Agreement, and the Initial Purchasers, on the basis of the
representations, warranties and agreements set forth herein and subject to the conditions set forth
herein, shall have the option to purchase, severally and not jointly, from the Company the Option
Securities at the Purchase Price plus accrued interest, if any, from the Closing Date to the date
of payment and delivery.

     If any Option Securities are to be purchased, the amount of Option Securities to be purchased
by each Initial Purchaser shall be the amount of Option Securities which bears the

 

3

same ratio to
the aggregate amount of Option Securities being purchased as the amount of Underwritten Securities
set forth opposite the name of such Initial Purchaser in Schedule 1 hereto (or such amount
increased as set forth in Section 10 hereof) bears to the aggregate amount of Underwritten
Securities being purchased from the Company by the several Initial Purchasers, subject, however, to
such adjustments to eliminate Securities in denominations other than $1,000 or any multiple of
$1,000 as the Representatives in its sole discretion shall make.

     The Initial Purchasers may exercise the option to purchase the Option Securities at any time
in whole, or from time to time in part, on or before the thirtieth day following the date of this
Agreement, by written notice from the Representatives to the Company. Such notice shall set forth
the aggregate amount of Option Securities as to which the option is being exercised and the date
and time when the Option Securities are to be delivered and paid for which may be the same date and
time as the Closing Date (as hereinafter defined) but shall not be earlier than the Closing Date
nor later than the tenth full business day (as hereinafter defined) after the date of such notice
(unless such time and date are postponed in accordance with the provisions of Section 10 hereof).
Any such notice given after the Closing Date shall be given at least two Business Days prior to the
date and time of delivery specified therein.

     (b) The Company understands that the Initial Purchasers intend to offer the
Securities for resale on the terms set forth in the Time of Sale Information. Each Initial
Purchaser, severally and not jointly, represents, warrants and agrees that:

     (i) it is a qualified institutional buyer within the meaning of Rule 144A under the
Securities Act (a “QIB”) and an accredited investor within the meaning of Rule 501(a) under
the Securities Act;

     (ii) it has not solicited offers for, or offered or sold, and will not solicit offers
for, or offer or sell, the Securities by means of any form of general solicitation or
general advertising within the meaning of Rule 502(c) of Regulation D under the Securities
Act (“Regulation D”) or in any manner involving a public offering within the meaning of
Section 4(2) of the Securities Act; and

     (iii) it has not solicited offers for, or offered or sold, and will not solicit offers
for, or offer or sell, the Securities as part of their initial offering except within the
United States to persons whom it reasonably believes to be QIBs in transactions pursuant to
Rule 144A under the Securities Act (“Rule 144A”) and in connection with each such sale, it
has taken or will take reasonable steps to ensure that the purchaser of the Securities is
aware that such sale is being made in reliance on Rule 144A; or

     (c) Each Initial Purchaser acknowledges and agrees that the Company and, for purposes of the
opinions to be delivered to the Initial Purchasers pursuant to Sections 6(f) and 6(g), counsel for
the Company and counsel for the Initial Purchasers, respectively, may rely upon the accuracy of the
representations and warranties of the Initial Purchasers, and compliance by
the Initial Purchasers with their agreements, contained in paragraph (b) above, and each Initial
Purchaser hereby consents to such reliance.

 

4

     (d) The Company acknowledges and agrees that the Initial Purchasers may offer and sell
Securities to or through any affiliate of an Initial Purchaser and that any such affiliate may
offer and sell Securities purchased by it to or through any Initial Purchaser.

     (e) Payment for the Securities shall be made by wire transfer in immediately available funds
to the account specified by the Company to the Representatives in the case of the Underwritten
Securities, at the offices of Davis Polk & Wardwell LLP at 10:00 A.M. New York City time on June
15, 2011, or at such other time or place on the same or such other date, not later than the fifth
business day thereafter, as the Representatives and the Company may agree upon in writing or, in
the case of the Option Securities, on the date and at the time and place specified by the
Representatives in the written notice of the Initial Purchasers’ election to purchase such Option
Securities. The time and date of such payment for the Underwritten Securities is referred to
herein as the “Closing Date” and the time and date for such payment for the Option Securities, if
other than the Closing Date, is herein referred to as the “Additional Closing Date”.

     Payment for the Securities to be purchased on the Closing Date or the Additional Closing Date,
as the case may be, shall be made against delivery to the nominee of DTC, for the respective
accounts of the several Initial Purchasers of the Securities to be purchased on such date of one or
more global notes representing the Securities (collectively, the “Global Note”), with any transfer
taxes payable in connection with the sale of such Securities duly paid by the Company. The Global
Note will be made available for inspection by the Representatives at the office of J.P. Morgan
Securities LLC set forth above not later than 1:00 P.M., New York City time, on the business day
prior to the Closing Date or the Additional Closing Date, as the case may be.

     (f) The Company acknowledges and agrees that the Initial Purchasers are acting solely in the
capacity of an arm’s length contractual counterparty to the Company with respect to the offering of
Securities contemplated hereby (including in connection with determining the terms of the offering)
and not as a financial advisor or a fiduciary to, or an agent of, the Company or any other person.
Additionally, neither the Representatives nor any other Initial Purchaser is advising the Company
or any other person as to any legal, tax, investment, accounting or regulatory matters in any
jurisdiction. The Company shall consult with its own advisors concerning such matters and shall be
responsible for making its own independent investigation and appraisal of the transactions
contemplated hereby, and the Initial Purchasers shall have no responsibility or liability to the
Company with respect thereto. Any review by the Initial Purchasers of the Company, the transactions
contemplated hereby or other matters relating to such transactions will be performed solely for the
benefit of the Initial Purchasers and shall not be on behalf of the Company.

     3. Representations and Warranties of the Company. The Company represents and warrants
to each Initial Purchaser that:

     (a) Preliminary Offering Memorandum. The Preliminary Offering Memorandum, as of its date, did
not contain any untrue statement of a material fact or omit to state a material fact necessary in
order to make the statements therein, in the light of the circumstances under which

 

5

they were made,
not misleading; provided that the Company makes no representation and warranty with respect
to any statements or omissions made in reliance upon and in conformity with information relating to
any Initial Purchaser furnished to the Company in writing by such Initial Purchaser through the
Representatives expressly for use in any Preliminary Offering Memorandum, it being understood and
agreed that the only such information furnished by any Initial Purchaser consists of the
information described as such in Section 7(b) hereof.

     (b) Time of Sale Information. The Time of Sale Information, at the Time of Sale, did not, and
at the Closing Date and as of the Additional Closing Date, as the case may be, will not, contain
any untrue statement of a material fact or omit to state a material fact necessary in order to make
the statements therein, in the light of the circumstances under which they were made, not
misleading; provided that the Company makes no representation and warranty with respect to
any statements or omissions made in reliance upon and in conformity with information relating to
any Initial Purchaser furnished to the Company in writing by such Initial Purchaser through the
Representatives expressly for use in such Time of Sale Information, it being understood and agreed
that the only such information furnished by any Initial Purchaser consists of the information
described as such in Section 7(b) hereof. No statement of material fact included in the Offering
Memorandum has been omitted from the Time of Sale Information and no statement of material fact
included in the Time of Sale Information that is required to be included in the Offering Memorandum
has been omitted therefrom.

     (c) Additional Written Communications. Other than the Preliminary Offering Memorandum and the
Offering Memorandum, the Company (including its agents and representatives, other than the Initial
Purchasers in their capacity as such) has not made, used, prepared, authorized, approved or
referred to and will not prepare, make, use, authorize, approve or refer to any “written
communication” (as defined in Rule 405 under the Securities Act) that constitutes an offer to sell
or solicitation of an offer to buy the Securities (each such communication by the Company or its
agents and representatives (other than a communication referred to in clauses (i), (ii) and (iii)
below) an “Issuer Written Communication”) other than (i) the Preliminary Offering Memorandum, (ii)
the Offering Memorandum, (iii) the documents listed on Annex B hereto, including a term sheet
substantially in the form of Annex C hereto, which constitute part of the Time of Sale Information,
and (iv) each electronic road show and any other written communications approved in writing in
advance by the Representatives. Each such Issuer Written Communication, when taken together with
the Time of Sale Information, did not, and at the Closing Date and as of the Additional Closing
Date, as the case may be, will not, contain any untrue statement of a material fact or omit to
state a material fact necessary in order to make the statements therein, in the light of the
circumstances under which they were made, not misleading; provided that the Company makes
no representation and warranty with respect to any statements or omissions made in each such Issuer
Written Communication in reliance upon and in conformity with information relating to any Initial
Purchaser furnished to the Company in writing by such Initial Purchaser through the Representatives
expressly for use in such Issuer
Written Communication, it being understood and agreed that the only such information furnished by
any Initial Purchaser consists of the information described as such in Section 7(b) hereof.

 

6

     (d) Offering Memorandum. As of the date of the Offering Memorandum and as of the Closing Date
and as of the Additional Closing Date, as the case may be, the Offering Memorandum does not and
will not contain any untrue statement of a material fact or omit to state a material fact necessary
in order to make the statements therein, in the light of the circumstances under which they were
made, not misleading; provided that the Company makes no representation and warranty with
respect to any statements or omissions made in reliance upon and in conformity with information
relating to any Initial Purchaser furnished to the Company in writing by such Initial Purchaser
through the Representatives expressly for use in the Offering Memorandum, it being understood and
agreed that the only such information furnished by any Initial Purchaser consists of the
information described as such in Section 7(b) hereof.

     (e) Incorporated Documents. The documents incorporated by reference in the Offering
Memorandum or the Time of Sale Information, when filed with the Commission complied or will comply,
as the case may be, in all material respects with the requirements of the Securities Exchange Act
of 1934, as amended, and the rules and regulations of the Commission thereunder (collectively, the
“Exchange Act”) and such documents did not and will not contain any untrue statement of a material
fact or omit to state a material fact required to be stated therein or necessary to make the
statements therein, in light of the circumstances under which they were made, not misleading.

     (f) Financial Statements. The financial statements and the related notes thereto of the
Company and its consolidated subsidiaries included or incorporated by reference in the Time of Sale
Information and the Offering Memorandum present fairly in all material respects the financial
position of the Company and its consolidated subsidiaries as of the dates indicated and the results
of their operations and the changes in their cash flows for the periods specified; such financial
statements have been prepared in conformity with U.S. generally accepted accounting principles
applied on a consistent basis throughout the periods covered thereby; the other financial
information included or incorporated by reference in the Time of Sale Information and the Offering
Memorandum has been derived from the accounting records of the Company and its consolidated
subsidiaries and presents fairly in all material respects the information shown thereby.

     (g) No Material Adverse Change. Since the date of the most recent financial statements of the
Company included or incorporated by reference in the Time of Sale Information and the Offering
Memorandum, (i) there has not been any change in the capital stock, long-term debt, notes payable
or current portion of long-term debt of the Company or any of its subsidiaries, or any dividend or
distribution of any kind declared, set aside for payment, paid or made by the Company on any class
of capital stock, or any material adverse change, or any development that is reasonably likely to
result in a material adverse change, in or affecting the business, properties, financial position,
stockholders’ equity, results of operations or prospects of the Company and its subsidiaries taken
as a whole; (ii) neither the Company nor any of its subsidiaries has entered into any transaction
or agreement that is material to the Company and its
subsidiaries taken as a whole or incurred any liability or obligation, direct or contingent, that
is material to the Company and its subsidiaries taken as a whole; and (iii) neither the Company nor
any of its subsidiaries has sustained any material loss or interference with its

 

7

business from
fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor
disturbance or dispute or any action, order or decree of any court or arbitrator or governmental or
regulatory authority, except in each case as otherwise disclosed in the Time of Sale Information
and the Offering Memorandum.

     (h) Organization and Good Standing. The Company and each of its significant subsidiaries (as
such term is defined in Rule 1-02(w) of Regulation S-X) have been duly organized or formed and are
validly existing and in good standing under the laws of their respective jurisdictions of
organization or formation, are duly qualified to do business and are in good standing in each
jurisdiction in which their respective ownership or lease of property or the conduct of their
respective businesses requires such qualification, and have all corporate or limited liability
company power and authority necessary to own or hold their respective properties and to conduct the
businesses in which they are engaged, except where the failure to be so qualified or in good
standing or have such power or authority would not, individually or in the aggregate, have a
material adverse effect on the business, properties, financial position, stockholders’ equity,
results of operations or prospects of the Company and its subsidiaries taken as a whole or on the
performance by the Company of its obligations under the Transaction Documents (as defined below) (a
“Material Adverse Effect”). The subsidiaries listed in Schedule 2 to this Agreement are the only
significant subsidiaries of the Company.

     (i) Capitalization. The Company has an authorized capitalization as set forth in the Time of
Sale Information and the Offering Memorandum under the heading “Capitalization”; all the
outstanding shares of capital stock of the Company have been duly and validly authorized and issued
and are fully paid and non-assessable and are not subject to any pre-emptive or similar rights;
except as described in or expressly contemplated by the Time of Sale Information and the Offering
Memorandum, there are no outstanding rights (including, without limitation, pre-emptive rights),
warrants or options to acquire, or instruments convertible into or exchangeable for, any shares of
capital stock or other equity interest in the Company or any of its subsidiaries, or any contract,
commitment, agreement, understanding or arrangement of any kind relating to the issuance of any
capital stock of the Company or any such subsidiary, any such convertible or exchangeable
securities or any such rights, warrants or options; the capital stock of the Company conforms in
all material respects to the description thereof contained in the Time of Sale Information and the
Offering Memorandum; and all the outstanding shares of capital stock or other equity interests of
each significant subsidiary owned, directly or indirectly, by the Company have been duly and
validly authorized and issued, are fully paid and non-assessable, other than as described in the
Time of Sale Information and the Offering Memorandum, and are owned directly or indirectly by the
Company, free and clear of any lien, charge, encumbrance, security interest, restriction on voting
or transfer or any other claim of any third party.

     (j) Stock Options. With respect to the stock options (the “Stock Options”) granted pursuant
to the stock-based compensation plans of the Company and its subsidiaries (the “Company Stock
Plans”), (i) each Stock Option intended to qualify as an “incentive stock option” under
Section 422 of the Code so qualifies, (ii) each grant of a Stock Option was duly authorized no
later than the date on which the grant of such Stock Option was by its terms to be effective (the
“Grant Date”) by all necessary corporate action, including, as applicable, approval by the board of
directors of the Company (or a duly constituted and authorized committee thereof) and any required
stockholder

 

8

approval by the necessary number of votes or written consents, and the award agreement
governing such grant (if any) was duly executed and delivered by each party thereto, (iii) each
such grant was made in accordance with the terms of the Company Stock Plans, the Exchange Act and
all other applicable laws and regulatory rules or requirements, including the rules of the Nasdaq
Global Select Market and any other exchange on which Company securities are traded, (iv) the per
share exercise price of each Stock Option was equal to the fair market value of a share of Common
Stock on the applicable Grant Date and (v) each such grant was properly accounted for in accordance
with GAAP in the financial statements (including the related notes) of the Company and disclosed in
the Company’s filings with the Commission in accordance with the Exchange Act and all other
applicable laws. The Company has not knowingly granted, and there is no and has been no policy or
practice of the Company of granting, Stock Options immediately prior to, or otherwise coordinate
the grant of Stock Options with, the release or other public announcement of material information
regarding the Company or its subsidiaries or their results of operations or prospects.

     (k) Due Authorization. The Company has full corporate power and authority to execute and
deliver this Agreement, the Indenture, the Securities and the Call Spread Confirmations,
(collectively, the “Transaction Documents”) and to perform its obligations hereunder and
thereunder; and all action required to be taken for the due and proper authorization, execution and
delivery by it of each of the Transaction Documents and the consummation by it of the transactions
contemplated thereby or by the Time of Sale Information and the Offering Memorandum has been duly
and validly taken.

     (l) The Indenture. The Indenture has been duly authorized by the Company and, when duly
executed and delivered in accordance with its terms by each of the parties thereto, will constitute
a valid and legally binding agreement of the Company enforceable against the Company in accordance
with its terms, except as enforceability may be limited by applicable bankruptcy, insolvency,
reorganization, moratorium or other similar laws relating to or affecting creditors’ rights
generally or by equitable principles relating to enforceability (collectively, the ““Enforceability
Exceptions”); and on the Closing Date, the Indenture will conform in all material respects to the
requirements of the Trust Indenture Act of 1939, as amended (the “Trust Indenture Act”), and the
rules and regulations of the Commission applicable to an indenture that is qualified thereunder.

     (m) Purchase Agreement. This Agreement has been duly authorized, executed and delivered by
the Company.

     (n) The Securities. The Securities have been duly authorized by the Company and, when duly
executed, authenticated, issued and delivered as provided in the Indenture and paid for as provided
herein, will be duly and validly issued and outstanding and will constitute valid and legally
binding obligations of the Company enforceable against the Company in accordance with
their terms, subject to the Enforceability Exceptions, and will be entitled to the benefits of
the Indenture.

     (o) The Underlying Securities. Upon issuance and delivery of the Securities in accordance
with this Agreement and the Indenture, the Securities will be convertible at the option of the
holder thereof into cash or a combination of cash and shares of the Underlying Securities in
accordance the terms of the Securities; the Underlying Securities reserved for issuance upon
conversion of the Securities have been duly authorized and reserved and, when issued upon

 

9

conversion of the Securities in accordance with the terms of the Securities, will be validly
issued, fully paid and non assessable, and the issuance of the Underlying Securities will not be
subject to any preemptive or similar rights.

     (p) Descriptions of the Transaction Documents. Each Transaction Document conforms in all
material respects to the description thereof contained in the Time of Sale Information and the
Offering Memorandum.

     (q) No Violation or Default. Neither the Company nor any of its significant subsidiaries is
(i) in violation of its charter or by-laws or similar organizational documents; (ii) in default,
and no event has occurred that, with notice or lapse of time or both, would constitute such a
default, in the due performance or observance of any term, covenant or condition contained in any
indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the
Company or any of its significant subsidiaries is a party or by which the Company or any of its
significant subsidiaries is bound or to which any of the property or assets of the Company or any
of its significant subsidiaries is subject; or (iii) in violation of any law or statute or any
judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory
authority, except, in the case of clauses (ii) and (iii) above, for any such default or violation
that would not, individually or in the aggregate, have a Material Adverse Effect.

     (r) No Conflicts. The execution, delivery and performance by the Company of each of the
Transaction Documents, the issuance and sale of the Securities (including the issuance of the
Underlying Securities upon conversion thereof) and the consummation of the transactions
contemplated by the Transaction Documents or the Time of Sale Information and the Offering
Memorandum will not (i) conflict with or result in a breach or violation of any of the terms or
provisions of, or constitute a default under, or result in the creation or imposition of any lien,
charge or encumbrance upon any property or assets of the Company or any of its significant
subsidiaries pursuant to, any indenture, mortgage, deed of trust, loan agreement or other agreement
or instrument to which the Company or any of its significant subsidiaries is a party or by which
the Company or any of its significant subsidiaries is bound or to which any of the property or
assets of the Company or any of its significant subsidiaries is subject, (ii) result in any
violation of the provisions of the charter or by-laws or similar organizational documents of the
Company or any of its significant subsidiaries or (iii) result in the violation of any law or
statute or any judgment, order, rule or regulation of any court or arbitrator or governmental or
regulatory authority , except, in the case of clauses (i) and (iii) above, for any such conflict,
breach, violation or default that would not, individually or in the aggregate, have a Material
Adverse Effect.

     (s) No Consents Required. No consent, approval, authorization, order, registration or
qualification of or with any court or arbitrator or governmental or regulatory authority is
required for the execution, delivery and performance by the Company of each of the Transaction
Documents, the issuance and sale of the Securities (including the issuance of the Underlying
Securities upon conversion thereof) and the consummation of the transactions contemplated by the
Transaction Documents or the Time of Sale Information and the Offering Memorandum, except for such
as have been obtained or such consents, approvals, authorizations, orders and registrations

 

10

or
qualifications as may be required under applicable state securities laws in connection with the
purchase and resale of the Securities by the Initial Purchasers.

     (t) Legal Proceedings. Except as described in the Time of Sale Information and the Offering
Memorandum, there are no legal, governmental or regulatory investigations, actions, suits or
proceedings pending to which the Company or any of its significant subsidiaries is or may be a
party or to which any property of the Company or any of its significant subsidiaries is or may be
the subject that, individually or in the aggregate, if determined adversely to the Company or any
of its significant subsidiaries, could reasonably be expected to have a Material Adverse Effect; no
such investigations, actions, suits or proceedings are threatened or, to the best knowledge of the
Company, contemplated by any governmental or regulatory authority or threatened by others.

     (u) Independent Accountants. PricewaterhouseCoopers LLP, who have audited certain financial
statements of the Company and its subsidiaries is an independent registered public accounting firm
with respect to the Company and its subsidiaries within the applicable rules and
regulations adopted by the Commission and the Public Company Accounting Oversight Board (United
States) and as required by the Securities Act.

     (v) Title to Real and Personal Property. The Company and its significant subsidiaries have
good and marketable title in fee simple to, or have valid rights to lease or otherwise use, all
items of real and personal property that are material to the respective businesses of the Company
and its significant subsidiaries, in each case free and clear of all liens, encumbrances, claims
and defects and imperfections of title except those that (i) are described in the Time of Sale
Information and the Offering Memorandum, (ii) do not materially interfere with the use made and
proposed to be made of such property by the Company and its subsidiaries or (iii) could not
reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.

     (w) Intellectual Property. Except as could not reasonably be expected, individually or in the
aggregate, to have a Material Adverse Effect, (i) the Company and its subsidiaries each owns or
possesses sufficient rights to use all patents, trademarks, service marks, trade names, domain
names, goodwill associated with the foregoing, copyrights, trade secrets and know-how (including
all registrations and applications for registration of the foregoing, as applicable) (collectively,
“Intellectual Property”) necessary for the conduct of their respective businesses, (ii) the conduct
of the respective businesses of the Company and its subsidiaries does not infringe, misappropriate
or otherwise violate the Intellectual Property of any third party, and (iii) the Company and its
subsidiaries have not received any notice of any threatened or pending claims of infringement,
misappropriation or other violation of any Intellectual Property of any third party.

     (x) No Undisclosed Relationships. No relationship, direct or indirect, exists between or
among the Company or any of its subsidiaries, on the one hand, and the directors, officers,
stockholders, customers or suppliers of the Company or any of its subsidiaries, on the other, that
is required by the Securities Act to be described in a registration statement to be filed with the
Commission and that is not so described in the Time of Sale Information and the Offering
Memorandum.

 

11

     (y) Investment Company Act. The Company is not and, after giving effect to the offering and
sale of the Securities and the application of the proceeds thereof as described in the Time of Sale
Information and the Offering Memorandum, will not be required to register as an “investment
company” or an entity “controlled” by an “investment company” within the meaning of the Investment
Company Act of 1940, as amended, and the rules and regulations of the Commission thereunder
(collectively, the “Investment Company Act”).

     (z) Taxes. Except as would not reasonably be expected, individually or in the aggregate, to
have a Material Adverse Effect,(i) the Company and its subsidiaries have paid all federal, state,
local and foreign taxes and filed all tax returns required to be paid or filed through the date
hereof, except for such taxes that are currently being contested in good faith and for which
adequate reserves have been created by the Company and its subsidiaries to the extent required by
U.S. GAAP; and (ii) except as otherwise disclosed in the Time of Sale Information and the Offering
Memorandum, there is no tax deficiency that has been, or could reasonably be expected to be,
asserted against the Company or any of its subsidiaries or any of their respective properties or
assets, except for such tax deficiencies that are currently being contested in good faith and for
which adequate reserves have been created by the Company and its subsidiaries to the extent
required by U.S. GAAP.

     (aa) Licenses and Permits. The Company and its subsidiaries possess all licenses,
certificates, permits and other authorizations issued by, and have made all declarations and
filings with, the appropriate federal, state, local or foreign governmental or regulatory
authorities that are necessary for the ownership or lease of their respective properties or the
conduct of their respective businesses as described in the Time of Sale Information and the
Offering Memorandum, except where the failure to possess or make the same would not, individually
or in the aggregate, have a Material Adverse Effect; and except as described in the Time of Sale
Information and the Offering Memorandum, neither the Company nor any of its subsidiaries has
received notice of any revocation or modification of any such license, certificate, permit or
authorization or has any reason to believe that any such license, certificate, permit or
authorization will not be renewed in the ordinary course.

     (bb) No Labor Disputes. No labor disturbance by or dispute with employees of the Company or
any of its subsidiaries exists or, to the best knowledge of the Company, is contemplated or
threatened and the Company is not aware of any existing or imminent labor disturbance by, or
dispute with, the employees of any of its or its subsidiaries’ principal
suppliers, contractors or customers, except, in each case, as would not have a Material Adverse
Effect.

     (cc) Compliance With Environmental Laws. (i) The Company and its subsidiaries (x) are, and at
all prior times were, in compliance with any and all applicable federal, state, local and foreign
laws, rules, regulations, requirements, decisions and orders relating to the protection of human
health or safety, the environment, natural resources, hazardous or toxic substances or wastes,
pollutants or contaminants (collectively, “Environmental Laws”), (y) have received and are in
compliance with all permits, licenses, certificates or other authorizations or approvals required
of them under applicable Environmental Laws to conduct their respective businesses, and (z) have
not received notice of any actual or potential liability under or relating to any Environmental
Laws, including for the investigation or remediation of any disposal or release of

 

12

hazardous or
toxic substances or wastes, pollutants or contaminants, and have no knowledge of any event or
condition that would reasonably be expected to result in any such notice, and (ii) there are no
costs or liabilities associated with Environmental Laws of or relating to the Company or its
subsidiaries, except in the case of each of (i) and (ii) above, for any such failure to comply, or
failure to receive required permits, licenses or approvals, or cost or liability, as would not,
individually or in the aggregate, have a Material Adverse Effect; and (iii) except as described in
each of the Time of Sale Information and the Offering Memorandum, (x) there are no proceedings that
are pending, or that are known to be contemplated, against the Company or any of its subsidiaries
under any Environmental Laws in which a governmental entity is also a party, other than such
proceedings regarding which it is reasonably believed no monetary sanctions of $100,000 or more
will be imposed, (y) the Company and its subsidiaries are not aware of any issues regarding
compliance with Environmental Laws, or liabilities or other obligations under Environmental Laws or
concerning hazardous or toxic substances or wastes, pollutants or contaminants, that could
reasonably be expected to have a material effect on the capital expenditures, earnings or
competitive position of the Company and its subsidiaries, and (z) none of the Company and its
subsidiaries anticipates material capital expenditures relating to any Environmental Laws.

     (dd) Hazardous Substances. There has been no storage, generation, transportation, handling,
treatment, disposal, discharge, emission, or other release of any kind of toxic wastes or hazardous
substances, including, but not limited to, any naturally occurring radioactive materials, brine,
drilling mud, crude oil, natural gas liquids and other petroleum materials, by, due to or caused by
the Company or any of its subsidiaries (or, to the best of the Company’s knowledge, any other
entity (including any predecessor) for whose acts or omissions the Company or any of its
subsidiaries is or could reasonably be expected to be liable) upon any of the property now or
previously owned or leased by the Company or any of its subsidiaries, or upon any other property,
in violation of any Environmental Laws or in a manner or to a location that could reasonably be
expected to give rise to any liability under the Environmental Laws, except for any violation or
liability which would not, individually or in the aggregate, have a Material Adverse Effect.

     (ee) Compliance With ERISA. (i) Each employee benefit plan, within the meaning of
Section 3(3) of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”),
for which the Company or any member of its “Controlled Group” (defined as any trade or business
which is a member of a controlled group of corporations within the meaning of Section 414 of the
Internal Revenue Code of 1986, as amended (the “Code”)) would have any liability (each, a “Plan”)
has been maintained in material compliance with its terms and the requirements of any applicable
statutes, orders, rules and regulations, including but not limited to ERISA and the Code; (ii) no
prohibited transaction, within the meaning of Section 406 of ERISA or Section 4975 of the Code, has
occurred with respect to any Plan excluding transactions effected pursuant to a statutory or
administrative exemption and excluding transactions that, individually or in the aggregate, would
not reasonably be expected to have a Material Adverse Effect; (iii) for each Plan that is subject
to the funding rules of Section 412 of the Code or Section 302 of ERISA, no “accumulated funding
deficiency” as defined in Section 412 of the Code, whether or not waived, has occurred or is
reasonably expected to occur; (iv) the fair market value of the assets of each Plan exceeds the
present value of all benefits accrued under such Plan (determined based on

 

13

those assumptions used
to fund such Plan) except to the extent that any such accumulated funding deficiency, individually
or in the aggregate, would not reasonably be expected to have a Material Adverse Effect; (v) no
“reportable event” (within the meaning of Section 4043(c) of ERISA) has occurred or is reasonably
expected to occur that, individually or in the aggregate, would not reasonably be expected to have
a Material Adverse Effect; and (vi) neither the Company nor any member of the Controlled Group has
incurred, nor reasonably expects to incur, any material liability under Title IV of ERISA (other
than contributions to the Plan or premiums to the PBGC, in the ordinary course and without default)
in respect of a Plan (including a “multiemployer plan”, within the meaning of Section 4001(a)(3) of
ERISA).

     (ff) Disclosure Controls. The Company maintains an effective system of “disclosure controls
and procedures” (as defined in Rule 13a-15(e) of the Exchange Act) that is designed to ensure that
information required to be disclosed by the Company in reports that it files or submits under the
Exchange Act is recorded, processed, summarized and reported within the time periods specified in
the Commission’s rules and forms, including controls and procedures designed to ensure that such
information is accumulated and communicated to the Company’s management as appropriate to allow
timely decisions regarding required disclosure. The Company has carried out evaluations of the
effectiveness of its disclosure controls and procedures as required by Rule 13a-15 of the Exchange
Act.

     (gg) Accounting Controls. The Company maintains a system of “internal control over financial
reporting” (as defined in Rule 13a-15(f) of the Exchange Act) that comply with the requirements of
the Exchange Act and have been designed by, or under the supervision of, their respective principal
executive and principal financial officers, or persons performing similar functions, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting
principles, including, but not limited to internal accounting controls sufficient to provide
reasonable assurance that (i) transactions are executed in accordance with management’s general or
specific authorizations; (ii) transactions are recorded as necessary to permit preparation of
financial statements in conformity with generally accepted accounting principles and to maintain
asset accountability; (iii) access to assets is permitted only in accordance with management’s
general or specific authorization; and (iv) the recorded accountability for assets is compared with
the existing
assets at reasonable intervals and appropriate action is taken with respect to any differences.
Except as disclosed in the Time of Sale Information and the Offering Memorandum, there are no
material weaknesses in the Company’s internal controls. The Company’s auditors and the Audit
Committee of the Board of Directors of the Company have been advised of: (i) all significant
deficiencies and material weaknesses in the design or operation of internal controls over financial
reporting which are reasonably likely to adversely affect the Company’s ability to record, process,
summarize and report financial information; and (ii) any fraud, whether or not material, that
involves management or other employees who have a significant role in the Company’s internal
controls over financial reporting.

     (hh) Insurance. The Company and its subsidiaries have insurance covering their respective
properties, operations, personnel and businesses, including business interruption insurance, which
insurance is in amounts and insures against such losses and risks as are adequate to protect the
Company and its subsidiaries and their respective businesses; and neither the Company nor any of
its subsidiaries has (i) received notice from any insurer or agent of such insurer that

 

14

capital
improvements or other expenditures are required or necessary to be made in order to continue such
insurance or (ii) any reason to believe that it will not be able to renew its existing insurance
coverage as and when such coverage expires or to obtain similar coverage at reasonable cost from
similar insurers as may be necessary to continue its business.

     (ii) No Unlawful Payments. Neither the Company nor any of its subsidiaries nor, to the best
knowledge of the Company, any director, officer, agent, employee or other person associated with or
acting on behalf of the Company or any of its subsidiaries has (i) used any corporate funds for any
unlawful contribution, gift, entertainment or other unlawful expense relating to political
activity; (ii) made any direct or indirect unlawful payment to any foreign or domestic government
official or employee from corporate funds; (iii) violated or is in violation of any provision of
the Foreign Corrupt Practices Act of 1977; or (iv) made any bribe, rebate, payoff, influence
payment, kickback or other unlawful payment.

     (jj) Compliance with Money Laundering Laws. The operations of the Company and its
subsidiaries are and have been conducted at all times in compliance with applicable financial
recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of
1970, as amended, the money laundering statutes of all jurisdictions, the rules and regulations
thereunder and any related or similar rules, regulations or guidelines, issued, administered or
enforced by any governmental agency (collectively, the “Money Laundering Laws”) and no action, suit
or proceeding by or before any court or governmental agency, authority or body or any arbitrator
involving the Company or any of its subsidiaries with respect to the Money Laundering Laws is
pending or, to the best knowledge of the Company, threatened.

     (kk) Compliance with OFAC. None of the Company, any of its subsidiaries or, to the knowledge
of the Company, any director, officer, agent, employee or affiliate of the Company or any of its
subsidiaries is currently subject to any U.S. sanctions administered by the Office of Foreign
Assets Control of the U.S. Department of the Treasury (“OFAC”); and the Company will not directly
or indirectly use the proceeds of the offering of the Securities hereunder, or lend, contribute or
otherwise make available such proceeds to any subsidiary, joint venture partner or
other person or entity, for the purpose of financing the activities of any person currently subject
to any U.S. sanctions administered by OFAC.

     (ll) No Restrictions on Subsidiaries. Other than pursuant to the terms of the Company’s
existing credit facility, no subsidiary of the Company is currently prohibited, directly or
indirectly, under any agreement or other instrument to which it is a party or is subject, from
paying any dividends to the Company, from making any other distribution on such subsidiary’s
capital stock, from repaying to the Company any loans or advances to such subsidiary from the
Company or from transferring any of such subsidiary’s properties or assets to the Company or any
other subsidiary of the Company.

     (mm) No Broker’s Fees. Neither the Company nor any of its subsidiaries is a party to any
contract, agreement or understanding with any person (other than this Agreement) that would give
rise to a valid claim against the Company or any of its subsidiaries or any Initial Purchaser for a
brokerage commission, finder’s fee or like payment in connection with the offering and sale of the
Securities.

 

15

     (nn) Rule 144A Eligibility. On the Closing Date, the Securities will not be of the same class
as securities listed on a national securities exchange registered under Section 6 of the Exchange
Act or quoted in an automated inter-dealer quotation system (as determined pursuant to Rule 144A
under the Securities Act); and each of the Time of Sale Information, as of the Time of Sale, and
the Offering Memorandum, as of its date, contains or will contain all the information that, if
requested by a prospective purchaser of the Securities, would be required to be provided to such
prospective purchaser pursuant to Rule 144A(d)(4) under the Securities Act.

     (oo) No Integration. Neither the Company nor any of its affiliates (as defined in Rule 501(b)
of Regulation D) has, directly or through any agent, sold, offered for sale, solicited offers to
buy or otherwise negotiated in respect of, any security (as defined in the Securities Act), that is
or will be integrated with the sale of the Securities in a manner that would require registration
of the Securities under the Securities Act.

     (pp) No General Solicitation or Directed Selling Efforts. None of the Company or any of its
affiliates or any other person acting on its or their behalf (other than the Initial Purchasers, as
to which no representation is made) has (i) solicited offers for, or offered or sold, the
Securities by means of any form of general solicitation or general advertising within the meaning
of Rule 502(c) of Regulation D or in any manner involving a public offering within the meaning of
Section 4(2) of the Securities Act or (ii) engaged in any directed selling efforts within the
meaning of Regulation S under the Securities Act (“Regulation S”), and all such persons have
complied with the offering restrictions requirement of Regulation S

     (qq) Securities Law Exemptions. Assuming the accuracy of the representations and warranties
of the Initial Purchasers contained in Section 2(b) and their compliance with their agreements set
forth therein, it is not necessary, in connection with the issuance and sale of the Securities to
the Initial Purchasers and the offer, resale and delivery of the Securities by the Initial
Purchasers in the manner contemplated by this Agreement, the Time of Sale Information and the
Offering Memorandum, to register the Securities under the Securities Act or to qualify the
Indenture under the Trust Indenture Act.

     (rr) No Stabilization. The Company has not taken, directly or indirectly, any action designed
to or that could reasonably be expected to cause or result in any stabilization or manipulation of
the price of the Securities.

     (tt) Margin Rules. Neither the issuance, sale and delivery of the Securities nor the
application of the proceeds thereof by the Company as described in the Time of Sale Information and
the Offering Memorandum will violate Regulation T, U or X of the Board of Governors of the Federal
Reserve System or any other regulation of such Board of Governors.

     (uu) Forward-Looking Statements. No forward-looking statement (within the meaning of Section
27A of the Securities Act and Section 21E of the Exchange Act) contained in the Time of Sale
Information and the Offering Memorandum has been made or reaffirmed without a reasonable basis or
has been disclosed other than in good faith.

 

16

     (vv) Statistical and Market Data. Nothing has come to the attention of the Company that has
caused the Company to believe that the statistical and market-related data included or incorporated
by reference in the Time of Sale Information and the Offering Memorandum is not based on or derived
from sources that are reliable and accurate in all material respects.

     (ww) Sarbanes-Oxley Act. The Company is in compliance in all material respects with the
applicable provisions of the Sarbanes-Oxley Act of 2002 and the rules and regulations promulgated
in connection therewith (the “Sarbanes-Oxley Act”), including Section 402 related to loans and
Sections 302 and 906 related to certifications.

     (xx) No Ratings. There are no securities or preferred stock of or guaranteed by the Company
or any of its subsidiaries that are rated by a “nationally recognized statistical rating
organization,” as such term is defined in Section 3(a)(62) of the Exchange Act.

     4. Further Agreements of the Company. The Company covenants and agrees with each
Initial Purchaser that:

     (a) Delivery of Copies. Until the completion of the sale of the Securities by the Initial
Purchasers, the Company will deliver to the Initial Purchasers as many copies of the Preliminary
Offering Memorandum, any other Time of Sale Information, any Issuer Written Communication and the
Offering Memorandum (including all amendments and supplements thereto) as the Representatives may
reasonably request.

     (b) Offering Memorandum, Amendments or Supplements. Before finalizing the Offering Memorandum
or making or distributing any amendment or supplement to any of the Time of Sale Information or the
Offering Memorandum or filing with the Commission any document that will be incorporated by
reference therein, the Company will furnish to the
Representatives and counsel for the Initial Purchasers a copy of the proposed Offering Memorandum
or such amendment or supplement or document to be incorporated by reference therein for review, and
will not distribute any such proposed Offering Memorandum or amendment or supplement to which the
Representatives reasonably objects or file any such document with the Commission without providing
the Representatives with a reasonable time to review.

     (c) Additional Written Communications. Before making, preparing, using, authorizing,
approving or referring to any Issuer Written Communication, the Company will furnish to the
Representatives and counsel for the Initial Purchasers a copy of such written communication for
review and will not make, prepare, use, authorize, approve or refer to any such written
communication to which the Representatives reasonably objects.

     (d) Notice to the Representatives. The Company will advise the Representatives promptly, and
confirm such advice in writing, (i) of the issuance by any governmental or regulatory authority of
any order preventing or suspending the use of any of the Time of Sale Information, any Issuer
Written Communication or the Offering Memorandum or the initiation or threatening of any proceeding
for that purpose; (ii) of the occurrence of any event at any time prior to the completion of the
initial offering of the Securities as a result of which any of the

 

17

Time of Sale Information, any
Issuer Written Communication or the Offering Memorandum as then amended or supplemented would
include any untrue statement of a material fact or omit to state a material fact necessary in order
to make the statements therein, in the light of the circumstances existing when such Time of Sale
Information, Issuer Written Communication or the Offering Memorandum is delivered to a purchaser,
not misleading; and (iii) of the receipt by the Company of any notice with respect to any
suspension of the qualification of the Securities for offer and sale in any jurisdiction or the
initiation or threatening of any proceeding for such purpose; and the Company will use its
reasonable best efforts to prevent the issuance of any such order preventing or suspending the use
of any of the Time of Sale Information, any Issuer Written Communication or the Offering Memorandum
or suspending any such qualification of the Securities and, if any such order is issued, will
obtain as soon as possible the withdrawal thereof.

     (e) Ongoing Compliance of the Offering Memorandum and Time of Sale Information. (1) If at any
time prior to the completion of the initial offering of the Securities (i) any event shall occur or
condition shall exist as a result of which the Offering Memorandum as then amended or supplemented
would include any untrue statement of a material fact or omit to state any material fact necessary
in order to make the statements therein, in the light of the circumstances existing when the
Offering Memorandum is delivered to a purchaser, not misleading or (ii) it is necessary to amend or
supplement the Offering Memorandum to comply with law, the Company will promptly notify the Initial
Purchasers thereof and forthwith prepare and, subject to paragraph (b) above, furnish to the
Initial Purchasers such amendments or supplements to the Offering Memorandum (or any document to be
filed with the Commission and incorporated by reference therein) as may be necessary so that the
statements in the Offering Memorandum as so amended or supplemented (or including such document to
be incorporated by reference therein) will not, in the light of the circumstances existing when the
Offering Memorandum is delivered to a
purchaser, be misleading or so that the Offering Memorandum will comply with law and (2) if at any
time prior to the Closing Date (i) any event shall occur or condition shall exist as a result of
which any of the Time of Sale Information as then amended or supplemented would include any untrue
statement of a material fact or omit to state any material fact necessary in order to make the
statements therein, in the light of the circumstances under which they were made, not misleading or
(ii) it is necessary to amend or supplement any of the Time of Sale Information to comply with law,
the Company will promptly notify the Initial Purchasers thereof and forthwith prepare and, subject
to paragraph (b) above, furnish to the Initial Purchasers such amendments or supplements to any of
the Time of Sale Information (or any document to be filed with the Commission and incorporated by
reference therein) as may be necessary so that the statements in any of the Time of Sale
Information as so amended or supplemented will not, in light of the circumstances under which they
were made, be misleading.

     (f) Blue Sky Compliance. The Company will qualify the Securities for offer and sale under the
securities or Blue Sky laws of such jurisdictions as the Representatives shall reasonably request
and will continue such qualifications in effect so long as required for the offering and resale of
the Securities; provided that the Company shall not be required to (i) qualify as a foreign
corporation or other entity or as a dealer in securities in any such jurisdiction where it would
not otherwise be required to so qualify, (ii) file any general consent to service of

 

18

process in any
such jurisdiction or (iii) subject itself to taxation in any such jurisdiction if it is not
otherwise so subject.

     (g) Clear Market. For a period of 90 days after the date of the Offering Memorandum, the
Company will not (i) offer, pledge, sell, contract to sell, sell any option or contract to
purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase,
or otherwise transfer or dispose of, directly or indirectly, or file with the Commission a
registration statement under the Securities Act relating to, any shares of Common Stock or any
securities convertible into or exercisable or exchangeable for Common Stock, or publicly disclose
the intention to make any offer, sale, pledge, disposition or filing, or (ii) enter into any swap
or other agreement that transfers, in whole or in part, any of the economic consequences of
ownership of the Common Stock or any such other securities, whether any such transaction described
in clause (i) or (ii) above is to be settled by delivery of Common Stock or such other securities,
in cash or otherwise, without the prior written consent of J.P. Morgan Securities LLC, Merrill
Lynch, Pierce, Fenner & Smith Incorporated and Morgan Stanley & Co. LLC, other than the Securities
to be sold hereunder and any shares of Common Stock of the Company issued upon the exercise of
options granted under existing employee stock option plans or shares offered under existing and
previously disclosed employee stock purchase plans.

     (i) Use of Proceeds. The Company will apply the net proceeds from the sale of the Securities
as described in the Time of Sale Information and the Offering Memorandum under the heading “Use of
Proceeds”.

     (j) No Stabilization. The Company will not take, directly or indirectly, any action designed
to or that could reasonably be expected to cause or result in any stabilization or manipulation of
the price of the Securities and will not take any action prohibited by Regulation M under the
Exchange Act in connection with the distribution of the Securities contemplated hereby.

     (k) Underlying Securities. The Company will reserve and keep available at all times, free of
pre-emptive rights, shares of Common Stock for the purpose of enabling the Company to satisfy all
obligations to issue the Underlying Securities upon conversion of the Securities (calculated after
giving effect to the maximum number of shares of Common Stock at such time issuable upon conversion
of the Securities upon the occurrence of any “make-whole fundamental
change” (as defined in the Offering Memorandum)). The Company will use its reasonable best efforts
to cause the Underlying Securities to be listed on the Nasdaq Global Select Market (the
“Exchange”).

     (l) Supplying Information. While the Securities remain outstanding and are “restricted
securities” within the meaning of Rule 144(a)(3) under the Securities Act, the Company will, during
any period in which the Company is not subject to and in compliance with Section 13 or 15(d) of the
Exchange Act, furnish to holders of the Securities, prospective purchasers of the Securities
designated by such holders and securities analysts, in each case upon request, the information
required to be delivered pursuant to Rule 144A(d)(4) under the Securities Act.

 

19

     (m) DTC. The Company will assist the Initial Purchasers in arranging for the Securities to
be eligible for clearance and settlement through DTC.

     (n) No Resales by the Company. During the period from the Closing Date until one year after
the Closing Date or the Option Closing Date, if applicable, the Company will not, and will not
permit any of its controlled affiliates (as defined in Rule 144 under the Securities Act) to,
resell any of the Securities that have been acquired by any of them, except for Securities
purchased by the Company or any of its affiliates and resold in a transaction registered under the
Securities Act.

     (o) No Integration. Neither the Company nor any of its affiliates (as defined in Rule 501(b)
of Regulation D) will, directly or through any agent, sell, offer for sale, solicit offers to buy
or otherwise negotiate in respect of, any security (as defined in the Securities Act), that is or
will be integrated with the sale of the Securities in a manner that would require registration of
the Securities under the Securities Act.

     (p) No General Solicitation or Directed Selling Efforts. None of the Company or any of its
affiliates or any other person acting on its or their behalf (other than the Initial Purchasers, as
to which no covenant is given) will (i) solicit offers for, or offer or sell, the Securities by
means of any form of general solicitation or general advertising within the meaning of Rule 502(c)
of Regulation D or in any manner involving a public offering within the meaning of Section 4(2) of
the Securities Act or (ii) engage in any directed selling efforts within the meaning
of Regulation S, and all such persons will comply with the offering restrictions requirement of
Regulation S.

     5. Certain Agreements of the Initial Purchasers. Each Initial Purchaser hereby
represents and agrees that it has not and will not use, authorize use of, refer to, or participate
in the planning for use of, any written communication that constitutes an offer to sell or the
solicitation of an offer to buy the Securities other than (i) the Preliminary Offering Memorandum
and the Offering Memorandum, (ii) a written communication that contains no “issuer information” (as
defined in Rule 433(h)(2) under the Securities Act) that was not included (including through
incorporation by reference) in the Preliminary Offering Memorandum or the Offering Memorandum,
(iii) any written communication listed on Annex B or prepared pursuant to Section 4(c) above
(including any electronic road show), (iv) any written communication prepared by such Initial
Purchaser and approved by the Company in advance in writing or (v) any written communication
relating to or that contains the terms of the Securities and/or other information that was included
(including through incorporation by reference) in the Preliminary Offering Memorandum or the
Offering Memorandum.

     6. Conditions of Initial Purchasers’ Obligations. The obligation of each Initial
Purchaser to purchase the Underwritten Securities on the Closing Date or the Option Securities on
the Additional Closing Date, as the case may be as provided herein is subject to the performance by
the Company of its covenants and other obligations hereunder and to the following additional
conditions:

 

20

     (a) Representations and Warranties. The representations and warranties of the Company
contained herein shall be true and correct on the date hereof and on and as of the Closing Date or
the Additional Closing Date, as the case may be; and the statements of the Company and its officers
made in any certificates delivered pursuant to this Agreement shall be true and correct on and as
of the Closing Date or the Additional Closing Date, as the case may be.

     (b) No Material Adverse Change. No event or condition of a type described in Section 3(g)
hereof shall have occurred or shall exist, which event or condition is not described in the Time of
Sale Information (excluding any amendment or supplement thereto) and the Offering Memorandum
(excluding any amendment or supplement thereto) and the effect of which in the judgment of the
Representatives makes it impracticable or inadvisable to proceed with the offering, sale or
delivery of the Securities on the Closing Date or the Additional Closing Date, as the case may be,
on the terms and in the manner contemplated by this Agreement, the Time of Sale Information and the
Offering Memorandum.

     (c) Officer’s Certificate. The Representatives shall have received on and as of the Closing
Date or the Additional Closing Date, as the case may be, a certificate of the chief financial
officer or chief accounting officer of the Company and one additional senior executive officer of
the Company who is satisfactory to the Representatives (i) confirming that such officers have
carefully reviewed the Time of Sale Information and the Offering Memorandum and, to the best
knowledge of such officers, the representations set forth in Sections 3(a) hereof
are true and correct, (ii) confirming that the other representations and warranties of the Company
in this Agreement are true and correct and that the Company has complied with all agreements and
satisfied all conditions on its part to be performed or satisfied hereunder at or prior to such
Closing Date and (iii) to the effect set forth in paragraph (b) above.

     (d) Comfort Letters. On the date of this Agreement and on the Closing Date or the Additional
Closing Date, as the case may be, PricewaterhouseCoopers LLP shall have furnished to the
Representatives, at the request of the Company, letters, dated the respective dates of delivery
thereof and addressed to the Initial Purchasers, in form and substance reasonably satisfactory to
the Representatives, containing statements and information of the type customarily included in
accountants’ “comfort letters” to underwriters with respect to the financial statements and certain
financial information contained or incorporated by reference in the Time of Sale Information and
the Offering Memorandum; provided, that the letter delivered on the Closing Date or the Additional
Closing Date, as the case may be shall use a “cut-off” date no more than three business days prior
to such Closing Date or such Additional Closing Date, as the case may be.

     (e) Opinion and 10b-5 Statement of Counsel for the Company. Latham & Watkins LLP, counsel for
the Company, shall have furnished to the Representatives, at the request of the Company, their
written opinion and 10b-5 statement, dated the Closing Date or the Additional Closing Date, as the
case may be, and addressed to the Initial Purchasers, in form and substance reasonably satisfactory
to the Representatives.

 

21

     (f) Opinion and 10b-5 Statement of Counsel for the Initial Purchasers. The Representatives
shall have received on and as of the Closing Date or the Additional Closing Date, as the case may
be, an opinion and 10b-5 statement of Davis Polk & Wardwell LLP, counsel for the Initial
Purchasers, with respect to such matters as the Representatives may reasonably request, and such
counsel shall have received such documents and information as they may reasonably request to enable
them to pass upon such matters.

     (g) No Legal Impediment to Issuance. No action shall have been taken and no statute, rule,
regulation or order shall have been enacted, adopted or issued by any federal, state or foreign
governmental or regulatory authority that would, as of the Closing Date or the Additional Closing
Date, as the case may be, prevent the issuance or sale of the Securities; and no injunction or
order of any federal, state or foreign court shall have been issued that would, as of the Closing
Date or the Additional Closing Date, as the case may be, prevent the issuance or sale of the
Securities.

     (h) Good Standing. The Representatives shall have received on and as of the Closing Date or
the Additional Closing Date, as the case may be, satisfactory evidence of the good standing of the
Company and its significant subsidiaries in their respective jurisdictions of incorporation or
formation as the Representatives may reasonably request, in each case in writing or any standard
form of telecommunication from the appropriate governmental authorities of such jurisdictions.

     (i) DTC. The Securities shall be eligible for clearance and settlement through DTC.

     (j) Exchange Listing. An application for the listing of the Underlying Securities shall have
been submitted to the Exchange.

     (k) Lock-up Agreements. The “lock-up” agreements, each substantially in the form of Exhibit A
hereto, between you and, the officers and directors of the Company set forth on Schedule 2 hereto
relating to sales and certain other dispositions of shares of Common Stock or certain other
securities, delivered to you on or before the date hereof, shall be full force and effect on the
Closing Date or Additional Closing Date, as the case may be.

     (l) The Company shall have entered into the Second Amended and Restated Credit agreement dated
as of June 8, 2011 with Bank of America, N.A., as Administrative Agent, Swing Line Lender and L/C
Issuer, JPMorgan Chase Bank as Syndication Agent, HSBC Bank USA, NA, RBC Captal Markets, Wells
Fargo Bank, N.A., Fifth Third Bank, DNB Nor Bank ASA and TD Bank, N.A., as Co-Documentation Agents,
and other lenders thereto.

     (m) Additional Documents. On or prior to the Closing Date or the Additional Closing Date, as
the case may be, the Company shall have furnished to the Representatives such further certificates
and documents as the Representatives may reasonably request.

     All opinions, letters, certificates and evidence mentioned above or elsewhere in this
Agreement shall be deemed to be in compliance with the provisions hereof only if they are in form
and substance reasonably satisfactory to counsel for the Initial Purchasers.

 

22

     7. Indemnification and Contribution.

     (a) Indemnification of the Initial Purchasers. The Company agrees to indemnify and hold
harmless each Initial Purchaser, its affiliates, directors and officers and each person, if any,
who controls such Initial Purchaser within the meaning of Section 15 of the Securities Act or
Section 20 of the Exchange Act, from and against any and all losses, claims, damages and
liabilities (including, without limitation, reasonable legal fees and other expenses incurred in
connection with any suit, action or proceeding or any claim asserted, as such fees and expenses are
incurred), joint or several, that arise out of, or are based upon, (i) any untrue statement or
alleged untrue statement of a material fact contained in the Preliminary Offering Memorandum, any
of the other Time of Sale Information, any Issuer Written Communication or the Offering Memorandum
(or any amendment or supplement thereto) or any omission or alleged omission to state therein a
material fact necessary in order to make the statements therein, in light of the circumstances
under which they were made, not misleading, in each case except insofar as such losses, claims,
damages or liabilities arise out of, or are based upon, any untrue statement or omission or alleged
untrue statement or omission made in reliance upon and in conformity with any information relating
to any Initial Purchaser furnished to the Company in writing by such Initial Purchaser through the
Representatives expressly for use therein, it being understood and agreed that the only such
information furnished by any Initial Purchaser consists of the information described as such in
subsection (b) below.

     (b) Indemnification of the Company. Each Initial Purchaser agrees, severally and not jointly,
to indemnify and hold harmless the Company, its directors, its officers and each person, if any,
who controls the Company within the meaning of Section 15 of the Securities Act or Section 20 of
the Exchange Act to the same extent as the indemnity set forth in paragraph (a) above, but only
with respect to any losses, claims, damages or liabilities that arise out of, or are based upon,
any untrue statement or omission or alleged untrue statement or omission made in reliance upon and
in conformity with any information relating to such Initial Purchaser furnished to the Company in
writing by such Initial Purchaser through the Representatives expressly for use in the Preliminary
Offering Memorandum, any of the other Time of Sale Information, any Issuer Written Communication or
the Offering Memorandum (or any amendment or supplement thereto), it being understood and agreed
upon that the only such information furnished by any Initial Purchaser consists of the following
information in the Preliminary Offering Memorandum and the Offering Memorandum furnished on behalf
of each Initial Purchaser: the ninth and twelfth paragraphs under the caption “Plan of
Distribution” of the Offering Memorandum.

     (c) Notice and Procedures. If any suit, action, proceeding (including any governmental or
regulatory investigation), claim or demand shall be brought or asserted against any person in
respect of which indemnification may be sought pursuant to either paragraph (a) or (b) above, such
person (the “Indemnified Person”) shall promptly notify the person against whom such
indemnification may be sought (the “Indemnifying Person”) in writing; provided that the
failure to notify the Indemnifying Person shall not relieve it from any liability that it may have
under paragraph (a) or (b) above except to the extent that it has been materially prejudiced
(through the forfeiture of substantive rights or defenses) by such failure; and provided,
further, that the failure to notify the Indemnifying Person shall not relieve it from any
liability that it may have to an Indemnified Person otherwise than under paragraph (a) or (b)
above. If any such proceeding shall

 

23

be brought or asserted against an Indemnified Person and it
shall have notified the Indemnifying Person thereof, the Indemnifying Person shall retain counsel
reasonably satisfactory to the Indemnified Person (who shall not, without the consent of the
Indemnified Person, be counsel to the Indemnifying Person) to represent the Indemnified Person in
such proceeding and shall pay the fees and expenses of such counsel related to such proceeding, as
incurred. In any such proceeding, any Indemnified Person shall have the right to retain its own
counsel, but the fees and expenses of such counsel shall be at the expense of such Indemnified
Person unless (i) the Indemnifying Person and the Indemnified Person shall have mutually agreed to
the contrary; (ii) the Indemnifying Person has failed within a reasonable time to retain counsel
reasonably satisfactory to the Indemnified Person; (iii) the Indemnified Person shall have
reasonably concluded that there may be legal defenses available to it that are different from or in
addition to those available to the Indemnifying Person; or (iv) the named parties in any such
proceeding (including any impleaded parties) include both the Indemnifying Person and the
Indemnified Person and representation of both parties by the same counsel would be inappropriate
due to actual or potential differing interest between them. It is understood and agreed that the
Indemnifying Person shall not, in connection with any proceeding or related proceeding in the same
jurisdiction, be liable for the fees and expenses of more than one separate firm (in addition to
any local counsel) for all Indemnified Persons, and that all such fees and expenses shall be paid
or reimbursed as they are incurred. Any such separate firm for any Initial Purchaser, its
affiliates, directors and officers and any control persons of such Initial Purchaser shall be
designated in writing by the Representatives and any such separate firm for the Company, its
directors, its officers and any control persons of the Company shall be designated in writing by
the Company. The Indemnifying Person shall not be liable for any settlement of any proceeding
effected without its written consent, but if settled with such consent or if there be a final
judgment for the plaintiff, the Indemnifying Person agrees to indemnify each Indemnified Person
from and against any loss or liability by reason of such settlement or judgment. Notwithstanding
the foregoing sentence, if at any time an Indemnified Person shall have requested that an
Indemnifying Person reimburse the Indemnified Person for fees and expenses of counsel as
contemplated by this paragraph, the Indemnifying Person shall be liable for any settlement of any
proceeding effected without its written consent if (i) such settlement is entered into more than 30
days after receipt by the Indemnifying Person of such request and (ii) the Indemnifying Person
shall not have reimbursed the Indemnified Person in accordance with such request prior to the date
of such settlement. No Indemnifying Person shall, without the written consent of the Indemnified
Person, effect any settlement of any pending or threatened proceeding in respect of which any
Indemnified Person is or could have been a party and indemnification could have been sought
hereunder by such Indemnified Person, unless such settlement (x) includes an unconditional release
of such Indemnified Person, in form and substance reasonably satisfactory to such Indemnified
Person, from all liability on claims that are the subject matter of such proceeding and (y) does
not include any statement as to or any admission of fault, culpability or a failure to act by or on
behalf of any Indemnified Person.

     (d) Contribution. If the indemnification provided for in paragraphs (a) and (b) above is
unavailable to an Indemnified Person or insufficient in respect of any losses, claims, damages or
liabilities referred to therein, then each Indemnifying Person under such paragraph, in lieu of
indemnifying such Indemnified Person thereunder, shall contribute to the amount paid or payable by
such Indemnified Person as a result of such losses, claims, damages or liabilities (i) in such

 

24

proportion as is appropriate to reflect the relative benefits received by the Company, on the one
hand, and the Initial Purchasers, on the other, from the offering of the Securities or (ii) if the
allocation provided by clause (i) is not permitted by applicable law, in such proportion as is
appropriate to reflect not only the relative benefits referred to in clause (i) but also the
relative fault of the Company, on the one hand, and the Initial Purchasers, on the other, in
connection with the statements or omissions that resulted in such losses, claims, damages or
liabilities, as well as any other relevant equitable considerations. The relative benefits
received by the Company, on the one hand, and the Initial Purchasers, on the other, shall be deemed
to be in the same respective proportions as the net proceeds (before deducting expenses) received
by the Company from the sale of the Securities and the total discounts and commissions received by
the Initial Purchasers in connection therewith, as provided in this Agreement, bear to the
aggregate offering price of the Securities. The relative fault of the Company, on the one hand,
and the Initial Purchasers, on the other, shall be determined by reference to, among other things,
whether the untrue or alleged untrue statement of a material fact or the omission or alleged
omission to state a material fact relates to information supplied by the Company or by the Initial
Purchasers and the parties’ relative intent, knowledge, access to information and opportunity to
correct or prevent such statement or omission.

     (e) Limitation on Liability. The Company and the Initial Purchasers agree that it would not
be just and equitable if contribution pursuant to this Section 7 were determined by pro
rata allocation (even if the Initial Purchasers were treated as one entity for such
purpose) or by any other method of allocation that does not take account of the equitable
considerations referred to in paragraph (d) above. The amount paid or payable by an Indemnified
Person as a result of the losses, claims, damages and liabilities referred to in paragraph (d)
above shall be deemed to include, subject to the limitations set forth above, any reasonable legal
or other expenses incurred by such Indemnified Person in connection with any such action or claim.
Notwithstanding the provisions of this Section 7, in no event shall an Initial Purchaser be
required to contribute any amount in excess of the amount by which the total discounts and
commissions received by such Initial Purchaser with respect to the offering of the Securities
exceeds the amount of any damages that such Initial Purchaser has otherwise been required to pay by
reason of such untrue or alleged untrue statement or omission or alleged omission. No person
guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act)
shall be entitled to contribution from any person who was not guilty of such fraudulent
misrepresentation. The Initial Purchasers’ obligations to contribute pursuant to this Section 7
are several in proportion to their respective purchase obligations hereunder and not joint.

     (f) Non-Exclusive Remedies. The remedies provided for in this Section 7 are not exclusive and
shall not limit any rights or remedies which may otherwise be available to any Indemnified Person
at law or in equity.

     8. Effectiveness of Agreement. This Agreement shall become effective upon the
execution and delivery hereof by the parties hereto.

     9. Termination. This Agreement may be terminated in the absolute discretion of the
Representatives, by notice to the Company, if after the execution and delivery of this Agreement

 

25

and prior to the Closing Date or, in the case of the Option Securities, prior to the Additional
Closing Date (i) trading generally shall have been suspended or materially limited on or by any of
the New York Stock Exchange, the NYSE Amex Equities or the Nasdaq Global Select Market; (ii)
trading of any securities issued or guaranteed by the Company shall have been suspended on any
exchange or in any over-the-counter market; (iii) a general moratorium on commercial banking
activities shall have been declared by federal or New York State authorities; or (iv) there shall
have occurred any outbreak or escalation of hostilities or any change in financial markets or any
calamity or crisis, either within or outside the United States, that, in the judgment of the
Representatives, is material and adverse and makes it impracticable or inadvisable to proceed with
the offering, sale or delivery of the Securities on the Closing Date or the Additional Closing
Date, as the case may be, on the terms and in the manner contemplated by this Agreement, the Time
of Sale Information and the Offering Memorandum.

     10. Defaulting Initial Purchaser. (a) If, on the Closing Date or the Additional
Closing Date, as the case may be, any Initial Purchaser defaults on its obligation to purchase the
Securities that it has agreed to purchase hereunder on such date, the non-defaulting Initial
Purchasers may in their discretion arrange for the purchase of such Securities by other persons
satisfactory to the Company on the terms contained in this Agreement. If, within 36 hours after
any such default by
any Initial Purchaser, the non-defaulting Initial Purchasers do not arrange for the purchase of
such Securities, then the Company shall be entitled to a further period of 36 hours within which to
procure other persons satisfactory to the non-defaulting Initial Purchasers to purchase such
Securities on such terms. If other persons become obligated or agree to purchase the Securities of
a defaulting Initial Purchaser, either the non-defaulting Initial Purchasers or the Company may
postpone the Closing Date or the Additional Closing Date, as the case may be, for up to five full
business days in order to effect any changes that in the opinion of counsel for the Company or
counsel for the Initial Purchasers may be necessary in the Time of Sale Information, the Offering
Memorandum or in any other document or arrangement, and the Company agrees to promptly prepare any
amendment or supplement to the Time of Sale Information or the Offering Memorandum that effects any
such changes. As used in this Agreement, the term “Initial Purchaser” includes, for all purposes
of this Agreement unless the context otherwise requires, any person not listed in Schedule 1 hereto
that, pursuant to this Section 10, purchases Securities that a defaulting Initial Purchaser agreed
but failed to purchase.

     (b) If, after giving effect to any arrangements for the purchase of the Securities of a
defaulting Initial Purchaser or Initial Purchasers by the non-defaulting Initial Purchasers and the
Company as provided in paragraph (a) above, the aggregate number of Securities that remain
unpurchased on the Closing Date or the Additional Closing Date, as the case may be does not exceed
one-eleventh of the aggregate number of Securities to be purchased on such date, then the Company
shall have the right to require each non-defaulting Initial Purchaser to purchase the number of
Securities that such Initial Purchaser agreed to purchase hereunder on such date plus such Initial
Purchaser’s pro rata share (based on the number of Securities that such Initial Purchaser agreed to
purchase on such date) of the Securities of such defaulting Initial Purchaser or Initial Purchasers
for which such arrangements have not been made.

     (c) If, after giving effect to any arrangements for the purchase of the Securities of a
defaulting Initial Purchaser or Initial Purchasers by the non-defaulting Initial Purchasers and the

 

26

Company as provided in paragraph (a) above, the aggregate number of Securities that remain
unpurchased on the Closing Date or the Additional Closing Date, as the case may be, exceeds
one-eleventh of the aggregate amount of Securities to be purchased on such date, or if the Company
shall not exercise the right described in paragraph (b) above, then this Agreement or, with respect
to any Additional Closing Date, the obligation of the Initial Purchasers to purchase Securities on
the Additional Closing Date, as the case may be, shall terminate without liability on the part of
the non-defaulting Initial Purchasers. Any termination of this Agreement pursuant to this Section
10 shall be without liability on the part of the Company, except that the Company will continue to
be liable for the payment of expenses as set forth in Section 11 hereof and except that the
provisions of Section 7 hereof shall not terminate and shall remain in effect.

     (d) Nothing contained herein shall relieve a defaulting Initial Purchaser of any liability it
may have to the Company or any non-defaulting Initial Purchaser for damages caused by its default.

     11. Payment of Expenses. (a) Whether or not the transactions contemplated by this
Agreement are consummated or this Agreement is terminated, the Company will pay or cause to
be paid all costs and expenses incident to the performance of its obligations hereunder, including
without limitation, (i) the costs incident to the authorization, issuance, sale, preparation and
delivery of the Securities and any taxes payable in that connection; (ii) the costs incident to the
preparation and printing of the Preliminary Offering Memorandum, any other Time of Sale
Information, any Issuer Written Communication and the Offering Memorandum (including any amendments
and supplements thereto) and the distribution thereof; (iii) the costs of reproducing and
distributing each of the Transaction Documents; (iv) the fees and expenses of the Company’s counsel
and independent accountants; (v) the fees and expenses incurred in connection with the registration
or qualification and determination of eligibility for investment of the Securities under the laws
of such jurisdictions as the Representatives may designate and the preparation, printing and
distribution of a Blue Sky Memorandum (including the related fees and expenses of counsel for the
Initial Purchasers in an aggregate amount not to exceed $10,000); (vi) any fees charged by rating
agencies for rating the Securities, if applicable; (vii) the fees and expenses of the Trustee and
any paying agent (including reasonable related fees and expenses of any counsel to such parties);
(viii) all expenses and application fees incurred in connection with the application for approval
of the Securities for book-entry transfer by DTC; (ix) all expenses incurred by the Company in
connection with any “road show” presentation to potential investors ; and (x) all expenses and
application fees related to the listing of the Underlying Securities on the Exchange.

     (b) If (i) this Agreement is terminated pursuant to Section 9, (ii) the Company for any reason
fails to tender the Securities for delivery to the Initial Purchasers or (iii) the Initial
Purchasers decline to purchase the Securities for any reason permitted under this Agreement, the
Company agrees to reimburse the Initial Purchasers for all out-of-pocket costs and expenses
(including the fees and expenses of their counsel) reasonably incurred by the Initial Purchasers in
connection with this Agreement and the offering contemplated hereby.

     12. Persons Entitled to Benefit of Agreement. This Agreement shall inure to the
benefit of and be binding upon the parties hereto and their respective successors and the officers
and directors and any controlling persons referred to in Section 7 hereof. Nothing in this
Agreement is intended or shall be construed to give any other person any legal or equitable right,

 

27

remedy or claim under or in respect of this Agreement or any provision contained herein. No
purchaser of Securities from any Initial Purchaser shall be deemed to be a successor merely by
reason of such purchase.

     13. Survival. The respective indemnities, rights of contribution, representations,
warranties and agreements of the Company and the Initial Purchasers contained in this Agreement or
made by or on behalf of the Company or the Initial Purchasers pursuant to this Agreement or any
certificate delivered pursuant hereto shall survive the delivery of and payment for the Securities
and shall remain in full force and effect, regardless of any termination of this Agreement or any
investigation made by or on behalf of the Company or the Initial Purchasers.

     14. Certain Defined Terms. For purposes of this Agreement, (a) except where otherwise
expressly provided, the term “affiliate” has the meaning set forth in Rule 405 under the Securities
Act; (b) the term “business day” means any day other than a day on which banks are permitted or
required to be closed in New York City; (c) the term “subsidiary” has the meaning set
forth in Rule 405 under the Securities Act; and (d) the term “significant subsidiary” has the
meaning set forth in Rule 1-02 of Regulation S-X under the Exchange Act.

     15. Miscellaneous. (a) Authority of the Representatives. Any action by the Initial
Purchasers hereunder may be taken by J.P. Morgan Securities LLC, Merrill Lynch, Pierce, Fenner &
Smith Incorporated, Morgan Stanley & Co. LLC, Deutsche Bank Securities Inc., Wells Fargo
Securities, LLC and RBC Capital Markets Corporation on behalf of the Initial Purchasers, and any
such action taken by J.P. Morgan Securities LLC, Merrill Lynch, Pierce, Fenner & Smith
Incorporated, Morgan Stanley & Co. LLC, Deutsche Bank Securities Inc., Wells Fargo Securities, LLC
and RBC Capital Markets shall be binding upon the Initial Purchasers.

     (b) Notices. All notices and other communications hereunder shall be in writing and shall be
deemed to have been duly given if mailed or transmitted and confirmed by any standard form of
telecommunication. Notices to the Initial Purchasers shall be given to the Representatives c/o
J.P. Morgan Securities LLC, 383 Madison Avenue, New York, New York 10179 (fax: (212) 622-8358);
Attention: Equity Syndicate Desk. Notices to the Company shall be given to it at 311 Enterprise
Drive Plainsboro, New Jersey 08536 , (fax: (609) 275-1082); Attention: General Counsel.

     (c) Governing Law. This Agreement and any claim, controversy or dispute arising under or
related to this Agreement shall be governed by and construed in accordance with the laws of the
State of New York without regard to the conflict of laws principles thereof (other than 5-1401 of
the General Obligation Law).

     (d) Counterparts. This Agreement may be signed in counterparts (which may include
counterparts delivered by any standard form of telecommunication), each of which shall be an
original and all of which together shall constitute one and the same instrument.

     (e) Amendments or Waivers. No amendment or waiver of any provision of this Agreement, nor any
consent or approval to any departure therefrom, shall in any event be effective unless the same
shall be in writing and signed by the parties hereto.

 

28

     (f) Headings. The headings herein are included for convenience of reference only and are not
intended to be part of, or to affect the meaning or interpretation of, this Agreement.

     (g) Xtract Research LLC. The Company hereby agrees that the Initial Purchasers may provide
copies of the Preliminary Offering Memorandum and the Offering Memorandum relating to the offering
of the Securities and any other agreements or documents relating thereto, including, without
limitation, trust indentures, to Xtract Research LLC (“Xtract”) following the completion of the
offering for inclusion in an online research service sponsored by Xtract, access to which is
restricted to “qualified institutional buyers” as defined in Rule 144A under the Securities Act.

 

29

     If the foregoing is in accordance with your understanding, please indicate your acceptance of
this Agreement by signing in the space provided below.

	 	 	 	 	 
	 	Very truly yours,

INTEGRA LIFESCIENCES

HOLDINGS CORPORATION

 	 
	 	By:  	 	 
	 	 	Name:  	 	 
	 	 	Title:  	 	 

 

30

	 	 	 	 	 

Accepted: June 9, 2011

J.P. MORGAN SECURITIES LLC

MERRILL LYNCH. PIERCE, FENNER & SMITH INCORPORATED

MORGAN STANLEY & CO. LLC

DEUTSCHE BANK SECURITIES INC.

RBC CAPITAL MARKETS, LLC

WELLS FARGO SECURITIES, LLC

For itself and on behalf of the

several Initial Purchasers listed

in Schedule 1 hereto.

	 	 	 	 	 

	By:

	 	J.P. MORGAN SECURITIES LLC	 	 
	 
	 	 	 	 
	By:
	 	 	 	 
	 

	 	 

Authorized Signatory
	 	 

 

31

Schedule 1

	 	 	 	 	 
	 	 	Principal Amount of	 
	 	 	Firm Securities to be	 
	Initial Purchaser	 	Purchased	 
	J.P. Morgan Securities LLC
	 	$	40,000,000	 
	Morgan Stanley & Co. LLC
	 	$	36,000,000	 
	Merrill Lynch, Pierce, Fenner & Smith Incorporated
	 	$	32,000,000	 
	Deutsche Bank Securities Inc.
	 	$	20,000,000	 
	RBC Capital Markets, LLC
	 	$	20,000,000	 
	Wells Fargo Securities, LLC
	 	$	20,000,000	 
	HSBC Securities (USA) Inc.
	 	$	8,000,000	 
	RBS Securities Inc.
	 	$	8,000,000	 
	Mitsubishi UFJ Securities (USA), Inc.
	 	$	6,000,000	 
	Piper Jaffray & Co.
	 	$	2,500,000	 
	Canaccord Genuity Inc.
	 	$	2,500,000	 
	Madison Williams and Company LLC
	 	$	2,500,000	 
	Oppenheimer & Co. Inc.
	 	$	2,500,000	 
	 
	 	 	 
	Total
	 	$	200,000,000	 
	 
	 	 	 

 

32

Schedule 2

Officers and Directors

	 	•	 	Stuart M. Essig
	 
	 	•	 	Peter J. Arduini
	 
	 	•	 	John B. Henneman
	 
	 	•	 	Judith E. O’Grady
	 
	 	•	 	Jerry E. Corbin
	 
	 	•	 	Thomas J. Baltimore, Jr.
	 
	 	•	 	Keith Bradley
	 
	 	•	 	Richard E. Caruso
	 
	 	•	 	Neal Moszkowski
	 
	 	•	 	Raymond G. Murphy
	 
	 	•	 	Christian S. Schade
	 
	 	•	 	James M. Sullivan
	 
	 	•	 	Anne M. VanLent

 

33

Annex B

a. Time of Sale Information

Term sheet containing the terms of the Securities, substantially in the form of Annex C.

 

34

Annex C

PRICING TERM SHEET

Dated June 9, 2011

Integra LifeSciences Holdings Corporation

1.625% Convertible Senior Notes due 2016

The information in this pricing term sheet supplements Integra LifeSciences Holdings
Corporation’s preliminary offering memorandum, dated June 9, 2011 (the “Preliminary Offering
Memorandum”), and supersedes the information in the Preliminary Offering Memorandum to the extent
inconsistent with the information in the Preliminary Offering Memorandum. In all other respects,
this term sheet is qualified in its entirety by reference to the Preliminary Offering Memorandum.
Terms used herein but not defined herein shall have the respective meanings as set forth in the
Preliminary Offering Memorandum. All references to dollar amounts are references to U.S. dollars.

	 	 	 

	Issuer:

	 	Integra LifeSciences Holdings Corporation (“Integra”)
	 
	 	 
	Ticker / Exchange:

	 	IART / The NASDAQ Global Select Market (“NASDAQ”)
	 
	 	 
	Title of securities:

	 	1.625% Convertible Senior Notes due 2016 (the “Notes”)
	 
	 	 
	Aggregate principal amount offered:

	 	$200,000,000 of Notes
	 
	 	 
	Offering price:

	 	The Notes will be issued at a price of 100% of their
principal amount, plus accrued interest, if any, from
June 15, 2011
	 
	 	 
	Over-allotment option:

	 	$30,000,000 principal amount of Notes
	 
	 	 
	Annual interest rate:

	 	The Notes will bear interest at a rate equal to 1.625%
per annum from June 15, 2011
	 
	 	 
	NASDAQ Last Reported Sale Price on
June 9, 2011:

	 	$46.70 per share of Integra common stock
	 
	 	 
	Conversion premium:

	 	Approximately 23% above the NASDAQ Last Reported Sale
Price on June 9, 2011
	 
	 	 
	Initial conversion price:

	 	Approximately $57.44 per share of Integra common stock
	 
	 	 
	Initial conversion rate:

	 	17.4092 shares of Integra common stock per $1,000
principal amount of Notes
	 
	 	 
	Interest payment dates:

	 	June 15 and December 15, commencing on December 15, 2011
	 
	 	 
	Maturity date:

	 	December 15, 2016
	 
	 	 
	Joint book-running managers:

	 	J.P. Morgan Securities LLC
	 

	 	Merrill Lynch, Pierce, Fenner & Smith Incorporated
	 

	 	Morgan Stanley & Co. LLC
	 

	 	Deutsche Bank Securities Inc.
	 

	 	RBC Capital Markets, LLC
	 

	 	Wells Fargo Securities, LLC
	 
	 	 
	Co-managers:

	 	HSBC Securities (USA) Inc.
	 

	 	RBS Securities Inc.
	 

	 	Mitsubishi UFJ Securities (USA), Inc.
	 

	 	Canaccord Genuity Inc.
	 

	 	Madison Williams and Company LLC
	 

	 	Oppenheimer & Co. Inc.

 

35

	 	 	 

	 

	 	Piper Jaffray & Co.
	 
	 	 
	Trade date:

	 	June 10, 2011
	 
	 	 
	Settlement date:

	 	June 15, 2011
	 
	 	 
	CUSIP:

	 	457985 AJ8
	 
	 	 
	ISIN:

	 	US457985AJ83
	 
	 	 
	Convertible note hedge and warrant
transactions:

	 	In connection with the pricing of the Notes, Integra
entered into convertible note hedge transactions with
one or more affiliates of the initial purchasers (the
“option counterparties”). Integra also entered into
warrant transactions with the option counterparties.
The convertible note hedge transactions are expected to
reduce potential dilution to Integra common stock upon
any conversion of Notes. The warrant transactions could
separately have a dilutive effect to the extent that
the market price per share of Integra common stock
exceeds the applicable strike price of the warrants.
However, subject to certain conditions as specified
under the terms of the warrant transactions, Integra
may elect to settle all or a portion of the warrant
transactions in cash. If the initial purchasers
exercise their over-allotment option, Integra may enter
into additional convertible note hedge and warrant
transactions.
	 
	 	 
	Use of proceeds:

	 	Integra estimates that the net proceeds from the Notes
offering, after deducting estimated fees and expenses
and the initial purchasers’ discounts and commissions,
will be approximately $194 million if the
over-allotment option is not exercised. Integra intends
to use:
	 
	 	 
	 

	 	•     a portion of the net proceeds to pay the cost
of the convertible note hedge transactions, taking into
account the proceeds to Integra of the warrant
transactions;

	 
	 	 
	 

	 	•     approximately $35 million to purchase shares of
Integra common stock at the closing of the sale of the
Notes; and

	 
	 	 
	 

	 	•     the balance of the net proceeds from the Notes
offering to repay a portion of the indebtedness under
Integra’s senior credit facility and for general
corporate purposes.

	 
	 	 
	 

	 	If the initial purchasers exercise their over-allotment
option, Integra may sell additional warrants. Integra
intends to use the resulting additional proceeds of the
sale of the additional Notes and any additional
warrants:
	 
	 	 
	 

	 	•     to pay the cost to Integra of entering into
additional convertible notes hedge transactions; and

	 
	 	 
	 

	 	•     for general corporate purposes, including to
repay a portion of the indebtedness under Integra’s
senior credit facility.

	 
	 	 
	Additional interest:

	 	If, and for so long as, the restrictive legend on the
Notes has not been removed, the Notes are assigned a
restricted CUSIP number or the Notes are not otherwise
freely tradable by holders other than Integra’s
affiliates (without restrictions pursuant to U.S.
securities law or the terms of the indenture or the
Notes) as of the 375th day after the last date of
original issuance of the Notes, Integra will pay
additional interest on the Notes at a rate equal to
0.50% per annum of the principal amount of Notes
outstanding until the Notes are freely

 

36

	 	 	 

	 

	 	tradable as
described above; provided that Integra will not pay
additional interest on the Notes for failure to remove
the restrictive legend on the Notes or failure to cause
the Notes to be assigned an unrestricted CUSIP number
unless Integra has received a request to remove such
legend and obtain an unrestricted CUSIP number by a
holder, any initial purchaser or the trustee on or
after the 335th day after the last date of original
issuance of the Notes. Additional interest will accrue
from (i) if such request has been delivered prior to
the 365th day after the last date of original issuance
of the Notes, the 375th day after such last date of
original issuance or (ii) otherwise, 10 days from the
delivery date of such request.
	 
	 	 
	Adjustment to conversion rate upon
a make-whole fundamental change:

	 	The table below sets forth the number of additional
shares, if any, of Integra common stock to be added to
the conversion rate per $1,000 principal amount of
Notes in connection with a “make-whole fundamental
change” as described in the Preliminary Offering
Memorandum, based on the stock price and effective date
of the make-whole fundamental change.

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Stock Price
	Effective date	 	$46.70	 	$50.00	 	$55.00	 	$60.00	 	$65.00	 	$70.00	 	$80.00	 	$90.00	 	$100.00	 	$120.00	 	$140.00
	 
	June 15, 2011
	 	 	4.0040	 	 	 	3.5561	 	 	 	2.7859	 	 	 	2.2125	 	 	 	1.7788	 	 	 	1.4462	 	 	 	0.9841	 	 	 	0.6914	 	 	 	0.4978	 	 	 	0.2702	 	 	 	0.1495	 
	December 15, 2011
	 	 	4.0040	 	 	 	3.5964	 	 	 	2.7939	 	 	 	2.1998	 	 	 	1.7536	 	 	 	1.4138	 	 	 	0.9471	 	 	 	0.6564	 	 	 	0.4672	 	 	 	0.2491	 	 	 	0.1359	 
	December 15, 2012
	 	 	4.0040	 	 	 	3.6490	 	 	 	2.7757	 	 	 	2.1379	 	 	 	1.6666	 	 	 	1.3144	 	 	 	0.8449	 	 	 	0.5649	 	 	 	0.3903	 	 	 	0.1993	 	 	 	0.1054	 
	December 15, 2013
	 	 	4.0040	 	 	 	3.6139	 	 	 	2.6660	 	 	 	1.9867	 	 	 	1.4968	 	 	 	1.1407	 	 	 	0.6872	 	 	 	0.4347	 	 	 	0.2877	 	 	 	0.1393	 	 	 	0.0714	 
	December 15, 2014
	 	 	4.0040	 	 	 	3.4247	 	 	 	2.3992	 	 	 	1.6872	 	 	 	1.1946	 	 	 	0.8544	 	 	 	0.4560	 	 	 	0.2616	 	 	 	0.1624	 	 	 	0.0754	 	 	 	0.0386	 
	December 15, 2015
	 	 	4.0040	 	 	 	3.0538	 	 	 	1.9132	 	 	 	1.1706	 	 	 	0.7047	 	 	 	0.4220	 	 	 	0.1581	 	 	 	0.0709	 	 	 	0.0410	 	 	 	0.0212	 	 	 	0.0115	 
	December 15, 2016
	 	 	4.0040	 	 	 	2.5908	 	 	 	0.7726	 	 	 	0.0000	 	 	 	0.0000	 	 	 	0.0000	 	 	 	0.0000	 	 	 	0.0000	 	 	 	0.0000	 	 	 	0.0000	 	 	 	0.0000	 

The exact stock prices and effective dates may not be set forth in the table above, in which
case:

	 	•	 	If the stock price is between two stock prices in the table or the effective date is
between two effective dates in the table, the number of additional shares will be
determined by a straight-line interpolation between the number of additional shares set
forth for the higher and lower stock prices and the earlier and later effective dates, as
applicable, based on a 365-day year.
	 
	 	•	 	If the stock price is greater than $140.00 per share (subject to adjustment in the same
manner as the stock prices set forth in the column headings of the table above), no
additional shares will be added to the conversion rate.
	 
	 	•	 	If the stock price is less than $46.70 per share (subject to adjustment in the same
manner as the stock prices set forth in the column headings of the table above), no
additional shares will be added to the conversion rate.

Notwithstanding the foregoing, in no event will the conversion rate per $1,000 principal amount of
Notes exceed 21.4132, subject to adjustment in the same manner as the conversion rate as set forth
under “Description of notes—Conversion rights—Conversion rate adjustments” in the Preliminary
Offering Memorandum.

 

37

General

This communication is intended for the sole use of the person to whom it is provided by the sender.

This communication shall not constitute an offer to sell or the solicitation of an offer to buy
securities nor shall there be any sale of these securities in any state in which such offer,
solicitation or sale would be unlawful prior to registration or qualification under the laws of any
such state.

The Notes and any shares of common stock issuable upon conversion of the Notes have not been, and
will not be, registered under the Securities Act of 1933, as amended (the “Securities Act”), or any
state securities laws. Accordingly, the Notes are being offered and sold only to “qualified
institutional buyers” as defined in Rule 144A promulgated under the Securities Act. The Notes are
not transferable except in accordance with the restrictions described under “Transfer restrictions”
in the Preliminary Offering Memorandum.

 

38

Exhibit A          

FORM OF LOCK-UP AGREEMENT

June __, 2011

J.P. Morgan Securities LLC

Merrill Lynch, Pierce, Fenner & Smith Incorporated

Morgan Stanley & Co. LLC

Deutsche Bank Securities Inc.

RBC Capital Markets, LLC

Wells Fargo Securities, LLC
 As
Representatives of the
 several
Initial Purchasers listed
 in
Schedule 1 hereto

c/o J.P. Morgan Securities LLC

383 Madison Avenue

New York, New York 10179

     Re: Integra LifeSciences Holdings Corporation — Rule 144A Offering

Ladies and Gentlemen:

     The undersigned understands that you, as Representatives of the several Initial Purchasers,
propose to enter into a Purchase Agreement (the “Purchase Agreement”) with Integra LifeSciences
Holdings Corporation, a Delaware corporation (the “Company”), providing for the purchase and resale
(the “Placement”) by the several Initial Purchasers named in Schedule 1 to the Purchase Agreement
(the “Initial Purchasers”), of Convertible Senior Notes due 2016, of the Company (the
“Securities”). Capitalized terms used herein and not otherwise defined shall have the meanings set
forth in the Purchase Agreement.

     In consideration of the Initial Purchasers’ agreement to purchase and make the Placement of
the Securities, and for other good and valuable consideration receipt of which is hereby
acknowledged, the undersigned hereby agrees that, without the prior written consent of J.P. Morgan
Securities LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated and Morgan Stanley & Co. LLC on
behalf of the Initial Purchasers, the undersigned will not, during the period ending 90 days after
the date of the offering memorandum relating to the Placement (the “Offering Memorandum”), (1)
offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option
or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or
dispose of, directly or indirectly, any shares of Common Stock, $0.01 per share par value, of the
Company (the “Common Stock”) or any securities convertible into or
exercisable or exchangeable for Common Stock (including, without limitation, Common Stock

 

39

or such
other securities which may be deemed to be beneficially owned by the undersigned in accordance with
the rules and regulations of the Securities and Exchange Commission and securities which may be
issued upon exercise of a stock option or warrant) (collectively, “Transfer”), or publicly disclose
the intention to make any offer, sale, pledge or disposition, (2) enter into any swap or other
agreement that transfers, in whole or in part, any of the economic consequences of ownership of the
Common Stock or such other securities, whether any such transaction described in clause (1) or (2)
above is to be settled by delivery of Common Stock or such other securities, in cash or otherwise
or (3) make any demand for or exercise any right with respect to the registration of any shares of
Common Stock or any security convertible into or exercisable or exchangeable for Common Stock, in
each case other than (A), the offer, sale, contract to sell, pledge, disposition or transfer of
Common Stock by officers and directors, not earlier than 45 days after the date of the Offering
Memorandum, if the number of shares involved in such transactions does not in the aggregate exceed
250,000 shares of Common Stock of the Company (it being understood and agreed that such 250,000
share limit is an aggregate limit that applies to all of the officers and directors of the Company
executing letter agreements like this one in connection with the Placement and that the Company
shall have the right to designate whether the undersigned may Transfer shares of Common Stock
pursuant to this clause (A)); and (B) the Transfer of shares of Common Stock or any securities
convertible into or exercisable or exchangeable for Common Stock (i) as a bona fide gift or gifts
(including to a trust), provided that each donee shall execute and deliver to the Representatives a
lock-up letter in the form of this paragraph; and provided, further, that in the
case of any Transfer pursuant to clause B(i), no filing by any party (donor or donee,) under the
Securities Exchange Act of 1934, as amended, or other public announcement shall be required or
shall be made voluntarily in connection with such Transfer (other than a filing on a Form 5 made
after the expiration of the 90-day period referred to above), (ii) by will or by intestacy, (iii)
deemed to occur upon the cashless exercise of options granted pursuant to the Company’s employee
benefit plans in existence on the date hereof, or (iv) to the Company in an amount necessary to
satisfy taxes payable in connection with awards granted pursuant to the Company’s employee benefit
plans in existence on the date hereof.1

     In furtherance of the foregoing, the Company, and any duly appointed transfer agent for the
registration or transfer of the securities described herein, are hereby authorized to decline to
make any transfer of securities if such transfer would constitute a violation or breach of this
Letter Agreement.

     The undersigned hereby represents and warrants that the undersigned has full power and
authority to enter into this Letter Agreement. All authority herein conferred or agreed to be
conferred and any obligations of the undersigned shall be binding upon the successors, assigns,
heirs or personal representatives of the undersigned.

     The undersigned understands that, if the Purchase Agreement does not become effective by June
30, 2011, or if the Purchase Agreement (other than the provisions thereof which survive
termination) shall terminate or be terminated prior to payment for and delivery of the Common

 

			
	1	 	For Stuart M. Essig and Richard E. Caruso:
or (v) in connection with the early termination of the undersigned’s previously
disclosed forward sale contract with Credit Suisse First Boston Capital LLC.

 

40

Stock to be sold thereunder, the undersigned shall be released form all obligations under this
Letter Agreement. The undersigned understands that the Initial Purchasers are entering into the
Purchase Agreement and proceeding with the Placement in reliance upon this Letter Agreement.

     This Letter Agreement and any claim, controversy or dispute arising under or related to this
Letter Agreement shall be governed by and construed in accordance with the laws of the State of New
York, without regard to the conflict of laws principles thereof (other than Section 5-1401 of the
General Obligations Law).

	 	 	 	 	 
	 	Very truly yours,

[NAME OF STOCKHOLDER]

 	 
	 	By:  	 	 
	 	 	Name:  	 	 
	 	 	Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00190-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00190-of-00352.parquet"}]]